Maternal milk feedings and cytomegalovirus infection in preterm infants in sweden by Omarsdottir, Soley
Thesis for doctoral degree (Ph.D.)
2015
MATERNAL MILK FEEDINGS AND 
CYTOMEGALOVIRUS INFECTION 
IN PRETERM INFANTS IN SWEDEN
Soley Omarsdottir
Th
esis fo
r d
o
cto
ral d
egree (Ph
.D
.)  2015
So
ley O
m
arsd
o
ttir
M
ATERN
A
L M
ILK FEED
IN
G
S A
N
D
 CYTO
M
EG
A
LO
V
IRU
S IN
FECTIO
N
 
IN
 PRETERM
 IN
FA
N
TS IN
 SW
ED
EN
From The Department of Medicine, Solna 
Karolinska Institutet, Stockholm, Sweden 
MATERNAL MILK FEEDINGS AND 
CYTOMEGALOVIRUS INFECTION IN 
PRETERM INFANTS IN SWEDEN 
Soley Omarsdottir 
 
Stockholm 2015 
 
From The Department of Medicine, Solna 
Karolinska Institutet, Stockholm, Sweden 
MATERNAL MILK FEEDINGS AND 
CYTOMEGALOVIRUS INFECTION IN 
PRETERM INFANTS IN SWEDEN 
Soley Omarsdottir 
 
Stockholm 2015 
 
 All previously published papers were reproduced with permission from the publisher. 
Cover: Eva Charlotte, born at 25 weeks gestation, is being fed mother’s milk at a postnatal 
age of 7 weeks.  
Photo by Andrew Hodges, with permission from Andrew and Marnie Hodges. 
Published by Karolinska Institutet. 
Printed by E-Print AB 2015 
© Soley Omarsdottir, 2015 
ISBN 978-91-7549-248-3 
 
  
 
All previously published papers were reproduced with permission from the publisher. 
Cover: Eva Charlotte, born at 25 weeks gestation, is being fed mother’s milk at a postnatal 
age of 7 weeks.  
Photo by Andrew Hodges, with permission from Andrew and Marnie Hodges. 
Published by Karolinska Institutet. 
Printed by E-Print AB 2015 
© Soley Omarsdottir, 2015 
ISBN 978-91-7549-248-3 
 
  
THE MILK OF HUMAN KINDNESS;  
THE ROMAN TALE OF CIMON AND PERO 
 
 
This painting, known as Roman Charity, portrays the exemplary story of Cimon and his 
daughter Pero, by the ancient Roman historian Valerius Maximus.  
Cimon is imprisoned with death penalty by starvation. Pero has recently given birth to a child 
and secretly breastfeeds her father during her visits in prison. One day, she is discovered by 
the authorities but her act of selflessness makes such an impression on them that her deed is 
forgiven and Cimon is released.  
The tale of Cimon and Pero has inspired many great artists since the time of Rome resulting 
in several paintings, carvings and sculptures depicting the story.  
  
Roman Charity.  
Guido Cagnacci (1601-1681). 
Oil on canvas. 
Museo de Arte de Ponce, 
Puerto Rico. 
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SUMMARY 
In Sweden, preterm infants are preferably fed human milk. Very preterm infants (< 32 weeks), 
who are unable to breastfeed, are fed with expressed maternal milk via a nasogastric tube. 
Mothers of these infants often experience difficulties in establishing and maintaining lactation. 
The majority of women excrete cytomegalovirus (CMV) in their breast milk. CMV transmitted 
through maternal milk can cause symptomatic infection in preterm infants presenting as a sepsis 
like syndrome, pneumonitis, hepatopathy or enterocolitis. Routine freezing of maternal milk 
decreases the CMV load in breast milk and is used in some neonatal centers to reduce CMV 
transmission to preterm infants.  
The aims of the studies in this thesis were to document existing routines pertaining to breast milk 
use for preterm infants in Sweden, to investigate predictors of maternal milk feedings in 
extremely preterm infants (EPIs, < 28 weeks), to evaluate the rate and clinical expression of 
postnatal CMV infection in EPIs, to evaluate the effect of routine freezing of maternal milk on 
CMV transmission rate, CMV associated disease and neonatal morbidity and mortality in EPIs 
and to evaluate the prevalence of CMV infection in intestinal specimens from infants with 
necrotizing enterocolitis (NEC), spontaneous intestinal perforation (SIP) and related surgical 
conditions. 
In a national cross sectional study in 2006 in Sweden, we found that 27 of 36 (75%) neonatal 
units had their own milk bank. Milk donors were screened for human immunodeficiency virus, 
human T-lymphotropic virus, and hepatitis B and C viruses by 27 (100%), 14 (52%), and 22 
(81%) of the milk banks, respectively. Bacterial culture was performed on donor milk in 24 
(89%) milk banks. Donor milk was pasteurized in 22 (81%) milk banks. In 11 of the 36 (31%) 
neonatal units maternal milk was frozen to reduce the risk of CMV transmission. Nutritional 
analysis of donor and/or maternal milk was performed in 25 (69%) units.  
In a prospective cohort study at the neonatal units in Stockholm, including 97 mothers and their 
singleton EPIs, predictors of maternal milk feedings in EPIs during the first 6 weeks of life and at 
discharge were evaluated. Favorable predictors of maternal milk feedings the first 6 weeks of life 
were high maternal milk feedings (>90%) at second week of life, maternal university education 
and Nordic origin of the mother. The proportion of maternal milk feedings the first 6 weeks of 
life and maternal age were positively associated to the provision of maternal milk feedings at 
discharge while maternal overweight was an unfavorable predictor. High maternal milk feedings 
(>90%) at second week of life, assisted reproduction technology and maternal employment were 
predictive factors for exclusive maternal milk feedings at discharge.  
Ten EPIs and their 6 mothers were included in a pilot study at the neonatal unit, Astrid Lindgrens 
Children´s hospital to evaluate the rate and clinical expression of breast milk induced CMV 
infection.  Five (83%) mothers were CMV-seropositive; of these, 4 (80%) excreted CMV-DNA 
in breast milk and 2 (40%) had a positive CMV culture. CMV was detected in the urine of 2/7 
(29%) EPIs fed with CMV-positive milk; both were fed with breast milk positive for CMV 
culture. One EPI, later diagnosed with cystic fibrosis, developed hepatic affection concurrent with 
CMV urine excretion.  
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In a randomized study at the neonatal units in Stockholm, evaluating the effect of routine freezing 
of maternal milk on postnatal CMV infection and neonatal outcome, 140 EPIs were randomized 
to be fed only freeze-thawed maternal milk (intervention group, IG) or both fresh maternal milk  
and freeze-thawed maternal milk (control group, CG). Outcome measures were CMV 
transmission rate and symptomatic infection in EPIs, neonatal mortality and morbidity during 
hospital stay. Fifty-six EPIs in the IG and 65 EPIs in the CG were included in the final per 
protocol analysis. We observed an overall low CMV transmission rate (8%) to EPIs from mothers 
with detectable CMV in breast milk. Routine freezing of maternal milk did not reduce the rate of 
CMV transmission (9% in IG vs 6% in CG). Congenital CMV infection was detected in 2% of 
screened infants. No infected EPI presented with clinical symptoms of CMV infection. Mortality 
rates were similar; 7% in the IG and 6% in the CG. Neonatal morbidity did not differ except for 
late onset Candida sepsis; the incidence was 12% in the CG while no case was observed in the 
IG. 
In a retrospective observational study, we investigated the occurrence of the CMV in 70 intestinal 
specimens from 61 infants with NEC, SIP and related surgical conditions at the Karolinska 
University Hospital Solna and Uppsala University Hospital. Ten intestinal specimens from 
autopsied infants without bowel disease were controls. By using immunohistochemistry (IHC), 
we detected the CMV specific proteins CMV-immediate early antigen (CMV-IEA) in 81% 
(57/70) and CMV-late antigen (CMV-LA) in 64% (45/70) of the intestinal specimens; 2/10 (20%) 
of the control specimens were positive for both antigens. Although CMV antigens were prevalent 
irrespective of pathologic diagnosis, they were most frequent in specimens with the pathologic 
diagnosis NEC and intestinal perforation; 95% and 89% of these tissue specimens were positive 
for CMV-IEA and CMV-LA, respectively. CMV infection was confirmed by CMV-DNA 
analysis in 4/10 (40%) CMV-IHC-positive intestinal samples using Taqman PCR after laser 
capture microdissection and in 13/13 (100%) CMV-IHC-positive intestinal samples by in situ 
hybridization.  
To conclude, human milk handling routines vary between neonatal units in Sweden and need to 
be standardized. Mothers of EPIs should aim for a high breast milk production immediately after 
delivery to optimize lactation success. Mothers who are young, overweight, of non-Nordic origin 
or without university education may need special lactation support. Postnatal CMV transmission 
from mothers excreting CMV in breast milk to EPIs was low (8%) and was not reduced by 
routine freezing of maternal milk. However, congenital CMV infection in EPIs was unexpectedly 
high (2%). No EPI infected by CMV presented with clinical symptoms. Routine freezing of 
maternal milk did not affect neonatal death in EPIs although it may have protected against fungal 
late onset sepsis. CMV infection was prevalent in intestinal specimens from infants with NEC, 
SIP and related surgical condition implicating a possible role of the virus in disease pathogenesis. 
More studies are needed to further evaluate the risk/benefit ratio of maternal milk feedings in 
EPIs with regard to the short-term and long-term effects of postnatal CMV infection.    
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1 INTRODUCTION 
Human milk is uniquely suited to the newborn infant. The use of human milk to feed all 
infants, including preterm infants (< 37 weeks), is strongly advocated because of the proven 
health, cognitive and psychological advantages on the breastfeeding infant extending onto 
infancy and adulthood.  However, mothers of preterm infants often experience difficulties to 
establish and sustain adequate milk supplies. Very preterm infants (<32 weeks) are unable to 
feed directly from the breast and mothers of these infants need to express breast milk that is 
thereafter stored and fed to the infants by a nasogastric tube. Subsequently, when the infant 
has developed sucking skills, the transition from gavage feeding to breastfeeding may fail.  
Cytomegalovirus (CMV) is a virus belonging to the herpes virus family. After primary 
infection the virus persists in the host and can be reactivated. Almost all mothers that have 
been infected by CMV excrete the virus in their milk after birth. Infants that are born term are 
protected by antibodies from their mothers and usually do not get ill when infected by CMV. 
However, preterm infants, especially extremely preterm infants (EPIs, < 28 weeks), have an 
immature immune system and lack these protective antibodies and can get seriously ill. One 
way of eliminating CMV from breast milk is to heat the milk but most heat procedures 
destroy many important nutritional and immunological constituents in the milk. Freezing 
maternal milk reduces the amount of the virus and does not have the same harmful effect on 
all milk components.  
In Sweden, breastfeeding and the use of breast milk is highly valued and preterm infants are 
preferably fed maternal milk. If the mother cannot produce sufficient milk, or the milk cannot 
be used, donor milk is used. However, the prevailing routines of breast milk use in the care of 
neonatal infants in Sweden have not been surveyed. Likewise, knowledge is warranted on 
how to augment breast milk production in mothers of preterm infants during their neonatal 
stay. In addition, the rate and clinical expression of breast milk acquired CMV infection has 
not been evaluated in premature infants in Sweden. Furthermore, due to the lack of consistent 
results in clinical studies, a consensus on how to handle maternal milk to the most preterm 
infants with CMV transmission in mind is still needed. Moreover, little is known whether 
CMV can transmit to the intestine in utero, at birth or postnatally via breast milk and 
contribute to the pathogenesis of bowel diseases in the neonate. 
In this thesis I have focused on finding an answer to the following questions:  
What are the current routines for breast milk handling in the neonatal units in Sweden? 
What factors are predictive for milk production in mothers of EPIs? 
What is the rate and clinical expression of breast milk acquired CMV infection in EPIs in 
Sweden? 
Can we prevent CMV transmission to EPIs by routine freezing of maternal milk and does 
routine freezing of maternal milk affect neonatal outcome? 
Can we detect CMV infection in the bowel of infants presenting with necrotizing 
enterocolitis, spontaneous intestinal perforation or related surgical conditions? 
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2 BACKGROUND 
2.1 HUMAN MILK AND BREASTFEEDING 
Human milk is considered the ideal nutrition for both the term and the preterm infant (1).  
The composition of human milk, comprising both nutritional and nonnutritive bioactive 
factors, is tailored to promote survival and healthy development in the human infant (2).  
Today, exclusive breastfeeding for the first six months of life, with continued breastfeeding 
for at least a year, is recommended for infant feeding (1). 
2.1.1 Historical perspectives 
2.1.1.1 Mammalia 
Human beings belong to the class Mammalia, a group of lactating animals characterized by 
the presence of breasts (mammae), which after giving birth secrete a fluid that fully 
comprises the nutritional requirements for to their young during a time period. This very 
ancient manner of nourishing the offspring dates some 100 million years ago, when the first 
mammals appeared (3).   
2.1.1.2 Early evidence of breastfeeding  
Abundant archeological findings of Middle Eastern pottery portraying lactating goddesses 
implicate that breastfeeding was held in high regard already as early as 3000 years Before 
Christ (BC) (3). In one of the oldest existing Egyptian medical writings, The Papyrus Ebers, 
recommendations are given on how to increase mothers milk supply, demonstrating that 
lactation failure was considered a definite problem during ancient Egyptian times (4): 
 “To get a supply of milk in a woman’s breast for suckling a child: Warm the bones of a sword fish in 
oil and rub her back with it.  
Or: Let the woman sit cross-legged and eat fragrant bread of soused durra, while rubbing the parts 
with the poppy plant.”  
The Papyrys Ebers (1150 BC) 
2.1.1.3 Wet nursing 
The use of a wet nurse, or “a woman who breastfeed another’s child” was practiced already 
as early as 2000 BC. Through time, wet nursing evolved from an alternative of need, if the 
mother experienced lactation failure or died from childbirth, to an alternative of choice for 
woman of high rank in the society (950 BC to 1800 Anno Domini (AD)) (5).  
In Greece, about 950 BC, wet nurses were frequently used in households of high social status, 
establishing a high position of responsibility taking care of the offsprings until adolescence 
(4).  
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In the medical treatise of Soranus of Ephesus (98 AD to 117 AD), addressing the choice of 
wet nurse in the 2
nd
 century AD, the use of the fingernail test to determine breast milk quality 
was described (5):  
“When a drop of breast milk was placed on a fingernail and the finger moved, the milk was not 
supposed to be so watery to assess the quality and consistency of breast milk that it ran all over the 
surface of the nail. When the fingernail was turned downward, the milk was not to be thick enough 
to cling to the nail. The consistency of the milk should range between the two extremes.”.  
In the Roman empire, between 300 BC and 400 AD, the wealthy made contracts with wet 
nurses to feed abandoned infants, often unwanted females, that were subsequently used as 
slaves in the household (5).  
During the Middle Ages (500 to 1500 AD), people believed that breast milk was magic and  
that physical and psychological characteristics of a wet nurse could be conveyed to the nursed 
infant. This resulted in aversion against the hiring of wet nurses whereas a mother nursing her 
own child was highly valued (5).   
Throughout the Renaissance period (1400 to 1700 AD), society displayed a preference for 
mothers breastfeeding their own children and wet nurses were disliked  (5). This is noticeably 
illustrated in the work “The nursing of children” by the French obstetrician Jacques 
Guillemeau published in the beginning of the 17
th
 century. In that work Guillemeau claims 
that there is “no difference between a woman who refuses to nurse her owne childe and one 
that kills her child as soon as she hath conceived” (6). The main objections that Guillemeau 
stated against wet nurse use were (5):  
“1) the child may be switched with another put in its place,  2) the affection felt between the child 
and the mother will diminish,  3) a bad condition may be inherited by the child and  
4) the nurse may transmit an imperfection of her own body to the child that could then be 
transmitted to the parents”. 
As Guillemeau believed that qualities of temperament could be conveyed by the milk he 
warned against wet nurses with red hair because redheads were known to have a hot 
temperament. If circumstances necessitated the use of a wet nurse, she should have the 
following characteristics according to Guillemeau (6): 
“She should be physically healthy, with a pleasing countenance, ‘ruddie mouth’, and rosy 
complexion, and she should have ‘veire white teeth’ and broad but not pendulous breasts with good 
nipples; she should play with her charge and change him often”.  
Regardless of these recommendations, wet nursing for the societal class remained a popular, 
well paid profession for many poor women during the Renaissance period. Aristocratic 
women in high social classes worried that breastfeeding would impair their health and ruin 
their figures. Essentially, to breastfeed interfered with social activities of the higher class, 
such as attending theaters and playing cards and prevented them from wearing socially 
acceptable clothing (6) .  
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With the onset of the Industrial revolution in the end of the 18
th
 century, wet nursing became 
more common in laboring lower income families. Women were forced to work to contribute 
financially to their families and were not able to attend and breastfeed their children (5).  
In the 19
th
 century, with the emergence of artificial feedings as a safe alternative to feed the 
infant, the demand of wet nurses diminished (7). Likewise, the establishment of wet-nursing 
regulations in order to decrease infant mortality led to fewer available wet nurses. In Sweden, 
the many supportive family policies that were introduced in the first half of the 20
th
 century 
may have had an additional role for the final disappearance of wet-nurses (8). Today, 
although the World Health Organization recommends breast milk from a healthy wet-nurse 
over artificial milk for  infants who are unable to breastfeed, wet-nursing is rare in the 
developed countries (9,10) 
2.1.1.4 Artificial feedings as a substitute to breastfeeding 
With the decreasing popularity of wet-nursing in the 19
th
 century, dry nursing i.e. feeding 
infants milk from animals became increasingly practiced. At the same time, physicians were 
enthusiastic to develop a more adequate substitute for mother´s milk (11). The first 
commercial infant formula was made by the chemist German Von Liebig in 1867.  This 
formula was composed of wheat flour, malt and potassium bicarbonate that was supposed to 
be mixed with preheated cow´s milk. As it soon became popular in Europe, some physicians 
endorsed the use of formula instead of hiring a wet nurse. Soon, in 1874, the first complete 
formula emerged that contained powdered cow´s milk, wheat flour, malt and sugar and only 
needed to be blended with water. At that time however, this formula was too expensive for 
the public majority (12). From 1890, pediatricians mostly recommended the use of artificial 
milk prepared by the “percentage method” by Rotch; a complex method that aimed at 
approximating the composition of cow´s milk close to that of human milk. This formula was 
principally used until 1915 after which commercial formula or home maid formula with 
evaporated milk took over (11). Concomitant with the developments described above, the 
The Dauphin Louis of France (1638-1715) and his 
Nursemaid, Dame Longuet de la Giraudiere.  
Oil on canvas. 
Beaubrun, Henri (1603-77) and Charles (1604-92) 
Château de Versailles, France. 
Giraudon , The Bridgeman Art Library. 
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manufacturing of glass feeding bottles and rubber teats helped to encourage the use of breast 
milk substitutes. 
By the establishment of refrigeration, allowing conservation of formulae together with 
promotional campaigns, the use of artificial feedings increased and breastfeeding rates 
declined. Moreover, during the feminist movement in the 1960s, feeding bottles were adopted 
as a symbol of women’s liberation, resulting in further decline of breastfeeding rates (12). In 
the United States in 1970, only 25% of newborn infants were fed any breast milk at 1 week 
postpartum (13). Thereafter, following the world breastfeeding support movement, 
breastfeeding popularity increased, and the trend was reversed with inclining breastfeeding 
rates in the industrialized countries. To date, knowledge about the benefits of breastfeeding is 
becoming increasingly clear and many countries have regulated the advertisement of artificial 
feedings and constituted maternal leave with the objective of increasing breastfeeding 
prevalence rates (12). 
2.1.1.5 Breastfeeding rates in Sweden 
There is no statistical information on breastfeeding rates in Sweden from earlier than the 20
th
 
century (14). In 1945, 95% of infants were fed with breast milk at 2 months; after that the 
frequency of breastfeeding began to decline. At that time, hospital deliveries were instituted 
and the maternal wards lacked adequate breastfeeding support for the mothers. In addition, 
more women began to work outside their homes. Concurrently, manufacturers of artificial 
feedings began to market their products leading to a further decrease in breastfeeding rates. 
In the early 1970s, the attitude towards breastfeeding in society altered. The social and 
medical benefits of breastfeeding where underlined and the trend changed, resulting in a 
sharp increase in breastfeeding rates (Figure 1). This trend was further reinforced in the 
mid-1990s by the establishment of the breastfeeding promotion program Baby Friendly 
Hospitals Initiative. Of infants born in 1998, 93% were being exclusively or partially 
breastfed at the age of two months and 73 % at the age of six months (15). However, since 
2004, the overall breastfeeding rates in Sweden have been successively decreasing resulting 
in a 10% reduction over a period of eight years in infants being exclusively or partially 
breastfed at the age of six months (15). 
Nonetheless, by international standards the frequency of breastfeeding in Sweden is still 
high. According to The National Board of Health and Welfare in Sweden, almost 96 per cent 
of infants born in 2012 were breastfed at the age of one week, about 86 per cent at the age 
of two months and at six months, 63 per cent were being exclusively or partially breastfed 
(15). In comparison, in the United States in 2009, the breastfeeding initiation rate was 77% 
and 47% were at least partly breastfed at 6 months (3). Similarly, according to a recent 
national cross-sectional study in Ireland, the breast feeding initiation rate was 56% and 8% 
of infants were at least partly breast fed at 9 months (17). 
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Figure 1 . The proportion of infants born 1964 to 2010 being exclusively breastfed at the age of 
2, 4 and 6 months, respectively. (The National Board of Health and Welfare in Sweden, Amning 
och föräldrars rökvanor. Barn födda 2010 (16)) 
2.1.2 Breast anatomy and physiology of lactation 
2.1.2.1 Breast structure  
The female adult breast is composed of two separate functional parts. The first of these 
contains the glandular tissue that is concerned with milk production. The second part is 
comprises tissues that make up and support the breast that includes breast fat, connective 
tissue, and muscles (18). 
The glandular tissue is composed of the alveolar gland with tree like ductular branching 
alveoli.  It consists of 15 to 20 lobes that subdivides into 20-40 lobuli, again dividing into10-
100 milk secreting units, or alveoli. The alveoli are composed of milk producing secretory 
cells surrounded by myoepithelial cells responsible for ejecting milk into the duct of the 
alveoli. Each alveolar gland then opens into a lactiferous duct  merging into a larger duct, the 
mammary duct, that opens on the surface of the nipple (Figure 2) (19).  
 
 
 
 7 
 
Figure 1 . The proportion of infants born 1964 to 2010 being exclusively breastfed at the age of 
2, 4 and 6 months, respectively. (The National Board of Health and Welfare in Sweden, Amning 
och föräldrars rökvanor. Barn födda 2010 (16)) 
2.1.2 Breast anatomy and physiology of lactation 
2.1.2.1 Breast structure  
The female adult breast is composed of two separate functional parts. The first of these 
contains the glandular tissue that is concerned with milk production. The second part is 
comprises tissues that make up and support the breast that includes breast fat, connective 
tissue, and muscles (18). 
The glandular tissue is composed of the alveolar gland with tree like ductular branching 
alveoli.  It consists of 15 to 20 lobes that subdivides into 20-40 lobuli, again dividing into10-
100 milk secreting units, or alveoli. The alveoli are composed of milk producing secretory 
cells surrounded by myoepithelial cells responsible for ejecting milk into the duct of the 
alveoli. Each alveolar gland then opens into a lactiferous duct  merging into a larger duct, the 
mammary duct, that opens on the surface of the nipple (Figure 2) (19).  
 
 
 8 
 
Figure 2. A simplified schematic drawing of  breast structure (Breastfeeding: A Guide for the 
Medical Profession 2011 (19)). 
2.1.2.2 Physiology of lactation 
In humans, the mammary gland undergoes substantial physiologic adaption postnatally in 
order to be able to nourish the newborn child. The mammary development after birth are 
divided into 4 stages; mammogenesis, lactogenesis (lactogenesis 1 and 2), lactation and 
involution (20).   
2.1.2.2.1 Mammogenesis 
Mammogenesis, or breast development, takes place under the stimulation of serum hormones 
before and at puberty, during the menstrual cycles and throughout pregnancy. The hormones 
estrogen and progesterone stimulate the developmental changes that occur before and at 
puberty and in association with the menstrual cycles. During pregnancy, accelerated growth 
and proliferation occurs in response to luteal and placental hormones. The hormones 
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placental lactogen, chorionic gonadotropin and prolactin stimulate breast growth, estrogen 
promotes ductular differentiation and progesterone endorses lobular formation (20). 
2.1.2.2.2 Lactogenesis 
Lactogenesis, or the initiation of milk secretion, is divided into two stages. Lactogenesis 1, or 
secretory differentiation, is the developing capacity of the mammary gland to secrete milk 
during pregnancy. Lactogenesis 2, or secretory activation, is the initiation of copious milk 
production after birth (21) 
LACTOGENESIS 1  
Lactogenesis 1occurs from midpregnancy to late pregnancy when the epithelial cells of the 
alveoli differentiate into secretory cells and initiate milk synthesis through prolactin 
stimulation. Milk is secreted into the alveolar ductules.   
LACTOGENESIS 2  
Lactogenesis 2 is triggered by the rapid fall of progesterone and estrogen that occurs after 
delivery of the placenta. Release of prolactin by the anterior pituitary, no longer inhibited by 
these hormones, is thereby substantially increased. This stage of lactogenesis is controlled by 
central hormone release, i.e. endocrine controlled. With lactogenesis 2, tight junction 
complexes between the alveolar cells that previously have been open close tightly, thereby 
enabling the onset of secretion of copious amounts of breast milk.  
2.1.2.2.3 Lactation 
Lactation, the maintenance of milk production, begins at about 9 days postpartum. At this 
stage, continuous milk synthesis is driven by milk removal from the breast, or autocrine 
control. When milk is removed from the breast the hypothalamus inhibits the release of 
prolactin inhibiting factor, which in turn stimulates the release of prolactin and milk synthesis 
(Figure 2) (21).  
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Figure 3. Release and effect of prolactin and oxytocin on milk production and milk ejection. 
(Breastfeeding and human lactation 2016 (21)) 
2.1.2.2.4 Oxytocin 
The hormone oxytocin is released by the posterior pituitary in response to suckling or nipple 
stimulation and causes the milk ejection reflex necessary for milk removal from the breast. 
After release, oxytocin interacts with the myoepithelial cells that contract thereby ejecting 
milk from the alveoli into the ducts where it becomes available to the breastfeeding infant 
(21). 
2.1.2.2.5 Involution 
Involution, the last stage of lactogenesis, occurs on average 40 days after last breastfeeding 
and is a process where the milk producing epithelial cells die and are replaced by fat cells 
(21).  
2.1.2.2.6 Delayed or failed lactogenesis 2 
Delayed lactogenesis 2 is defined as a longer than usual phase between lactogenesis 1 and 
lactogenesis 2, or an onset greater than 72 hours after delivery (2). Failed lactogenesis 2 is 
defined as a failure to achieve full lactation; it can be caused by a primary inability of the 
mother to produce enough breast milk or be secondary to improper breastfeeding 
management and/or infant related problems (22). 
In addition to maternal anatomical or hormonal aberrations that can affect the physiological 
processes involved in lactogenesis, several maternal and infant factors that delay 
breastfeeding initiation and/or breast stimulation can cause a failure or delay in lactogenesis 2 
(22–24).  
Table 1 lists known risk factors for delayed or failed lactogenesis 2.  
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TABLE 1.  Risk factors for primary delayed or failed lactogenesis 2   
(Modified from Hurst NM. 2007 (22–24)) 
Delayed lactogenesis 2 
Age ≥ 30 years 
Primiparity 
Psychosocial stress/pain 
Maternal obesity 
Diabetes 
Hypertension 
Preterm birth  
Unscheduled cesarean section 
Stressful labor and delivery 
Long duration of stage 2 labor 
Prelacteal feeds, delayed first breastfeed episode 
Infant birth weight > 3600 grams 
Low perinatal breastfeeding frequency 
Flat or inverted nipples 
Nipple discomfort at day 0-3 postpartum  
Hormonal contraceptive administration during the first week postpartum 
Failed lactogenesis 2 
Cigarette smoking  
Breast surgery/injury 
Insufficient mammary glandular tissue 
Hypothyroidism, hypopituitarism 
Ovarian theca-lutein cyst 
Polycystic ovarian syndrome 
Retained placental fragments 
Postpartum hemorrhage with Sheehan´s syndrome 
Maternal medication  
Pseudoephedrine, estrogen containing birth control methods 
Incomplete breast emptying  
Improper latch on, scheduled feedings, supplemental feedings, pacifier overuse  
Ineffective suck of infant  
Preterm birth, tongue-tie, cleft-palate, congenital heart disease 
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2.1.3 The composition of human milk  
Human milk is the ideal nutrition for the human infant, encompassing unique nutritional and 
bioactive factors that promote infant growth and development. As a complete overview of 
human milk composition is beyond the scope of this thesis a selected number of nutritional 
and bioactive milk components will be characterized.   
2.1.3.1 Colostrum, transitional milk and mature milk 
The first milk produced by mothers after delivery is colostrum. Compared to transitional and 
mature milk, proteins are present in high amounts but fat and carbohydrate concentrations are 
lower, keeping with the needs and reserves of the newborn infant (25). Colostrum is very rich 
in secretory immunoglobulin A (IgA), lactoferrin, leukocytes and oligosaccharides and 
contains epidermal growth factor (EGF)  highlighting its important immunologic and trophic 
role in the neonate (2). 
With the shift from lactogenesis 1 to lactogenesis 2 and closure of the gaps in the mammary 
epithelium, a 2-4 week period of ramped up milk production begins. During this period 
transitional milk is produced with increasing carbohydrate and lipid content to fulfill the 
infants increasing nutritional demands. By the end of the period, at 4-6 weeks, human milk is 
considered fully mature and remains relatively similar in composition throughout the rest of 
the lactation period (2). 
2.1.3.2 Nutritional components 
2.1.3.2.1 MACRONUTRIENTS 
The macronutrient composition (protein, fat, lactose) of human milk varies within mothers 
and during the course of lactation. 
PROTEIN 
The mean protein content of mature term human milk is about 0.9 to 1.2 g/dL whereas the 
concentration in human milk after preterm birth is significantly higher depending on age of 
gestation at delivery (2,26–28). Regardless of the time of delivery, protein levels in human 
milk decrease during the first 8 weeks of life (Figure 3) (2,27).  
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Figure 4. Milk protein concentrations from term and preterm mothers the first 8 weeks of life.  
(Ballard  O, Morrow AL. 2013 (2)) 
FAT 
Fat is the main provider of calories in human milk and is the most variable milk component 
(2,25).  The total fat of human milk ranges from 2.2 to 6.2 g/dL (average 4.1 g/dL) and is 
higher in milk of preterm mothers, in afternoon and evening feedings and at the end of 
feedings (27,29,30). Milk fat is mainly composed triacylglycerols (98-99%) with lesser 
amounts of mono- and diacylglycerols, non-esterified fatty acids, cholesterol and 
phospholipids. The composition of fatty acids in human milk favors lipid absorption and 
digestion in the infant thereby supporting an adequate energy supply. Postnatally, human 
milk is an important source of long-chain polyunsaturated fatty acids such as decosahexanoic 
acid  and arachidonic acid  shown to enhance visual acuity and cognitive development by 
their uptake into the membranes of the retina and brain (31,32). Human milk fatty acids are 
dependent on maternal diet and body stores; therefore, some expert panels recommend 
frequent intake of omega-3 rich fish or supplemental decosahexanoic acid  while 
breastfeeding (33,34). 
LACTOSE 
The disaccharide lactose accounts for most of the carbohydrates in human milk. Lactose in 
human milk is the most constant of the macronutrients (2). Lactose concentrations are 
relatively low in colostrum and in early lactation after which it increases to an average 
concentration of 6g/dL (35). Studies on the effect of preterm birth on lactose milk levels are 
contradictory;  some studies show lower lactose content in preterm milk (36) but others do 
not (37,38). 
2.1.3.2.2 MICRONUTRIENTS 
In general, human milk will satisfy the micronutrient requirements of a healthy full term 
infant. However, the concentration of several micronutrients in human milk rely on  maternal 
diet including vitamins A, B1, B2, B6, B12, D and iodine. If the maternal diet is not optimal, 
multivitamins during lactation is advocated (39). Vitamin D-supplement is recommended for 
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all breastfed infants in Sweden from the postnatal age of 1 week (40). When maternal body 
stores of iron are adequate, the amount of iron in human milk suffices for 4 to 6 months in the 
full term normal weight infant (41). Breastfed infants with a birth weight below 2500 g are at 
risk of iron deficiency, due to low iron deposits and rapid postnatal growth, and need 
supplemental iron from the postnatal age of 6 weeks in order to prevent iron deficiency and 
iron deficiency anemia(42,43) . Preterm infants fed human milk usually need special oral 
supplement of micronutrients (44), Injection of vitamin K to avoid hemorrhagic disease of the 
newborn is recommended in all infants after delivery as vitamin K is present in extremely low 
amounts in human milk (39).   
2.1.3.3 Bioactive components 
Bioactive components of human milk are factors with biological qualities that  contribute to 
infant health and survival through enzyme activities, growth stimulation, enhancement of 
nutrient absorption, modulation of the immune system and defense against pathogens (2,45).  
2.1.3.3.1 ENZYMES 
LYSOZYME 
Lysozyme is an enzyme which is present in high concentration in breast milk (400 µg/ml) 
and in higher concentrations in the preterm milk (46–48). It is an antibacterial enzyme that 
exerts its activity against bacteria by degrading their cell wall (45). 
AMYLASE 
Amylase is an enzyme that is synthesized in the pancreas and salivary glands and is necessary 
for the digestion of starch. Human milk contains significant amounts of salivary amylase. In 
newborns, amylase from the pancreas is not released into the gut the first 6 months of life. 
During this period, human milk amylase is believed to contribute to the infants ability to 
digest starch (48).  
LIPASE 
The bile-salt stimulated lipase and lipoprotein lipase in human milk aid in the digestion of 
lipids and compensate for the immature pancreatic function and the absence of amylase in 
neonates, especially in the premature infant (48). 
2.1.3.3.2 GROWTH FACTORS 
EPIDERMAL GROWTH FACTOR 
Epidermal growth factor (EGF) stimulates the proliferation and differentiation of the 
intestinal epithelial cells and exerts protective and healing mechanisms in the infant intestine 
(2,49). Breast milk from mothers of EPIs contains higher levels of EGF than breast milk from 
mothers of older preterm infants or mothers of term infants and the EGF levels are stable 
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during lactation in the first month of life (50,51). In term infants, EGF concentrations are 
highest in early milk and decrease over lactation (52).  
NEUROTROPHIC FACTORS 
Brain-derived neurotrophic factor and Glial cell line-derived neurotrophic factor promote 
development of the enteral nervous system and can be detected in milk in up to 90 days 
following delivery (2,53).  
VASCULAR ENDOTHELIAL GROWTH FACTOR 
Vascular Endothelial Growth Factor (VEGF) is important in angiogenesis and its presence in 
human milk may have a role in retinopathy of prematurity (ROP, see below). VEGF 
concentration is higher in early milk (day 3 ) than mature milk (day 28) in both preterm and 
term human milk but lower in early preterm milk than in early term milk (54). 
2.1.3.3.3 HORMONES  
ERYTHROPOIETIN 
Erythropoietin (EPO) is a hormone critical for the formation of red blood cells and is found in 
substantial quantities in human milk although variable between mothers and over time (55). 
EPO receptors have also been found in the intestinal mucosa  and experimental studies 
suggest that enteral EPO may have a stabilizing and protecting role for the intestinal barrier in 
early life (56,57)  
ADIPONECTIN 
Adiponectin is a hormone with a metabolic regulatory role. It is found in large quantities in 
human milk and may contribute to a lower incidence of overweight and obesity later in life in 
breastfed infants  (58,59). 
INSULIN LIKE GROWTH FACTOR-1  
Insulin like growth factor -1 (IGF-1) is a polypeptide with a growth promoting role found in 
in human milk (48). Levels are highest immediately after birth, decrease with lactation and do 
not differ in term and preterm milk (2). IGF-1 is important for early postnatal growth in 
preterm infants (60), contributes to gastrointestinal development (61) and  protects against 
ROP (62)(see below).     
2.1.3.3.4 IMMUNOLOGIC FACTORS 
Human milk is enriched with immune factors that protect against infection and promote the 
development of the infant immune system (63). 
HUMAN MILK CELLS  
Human milk, especially colostrum, contains a variety of leukocytes derived from the maternal 
circulation, including granulocytes, macrophages, monocytes and lymphocytes (64). Higher 
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counts of milk leukocytes are found in colostrum and in milk of preterm mothers (65). Milk 
leukocytes are thought to confer active immunity and to modulate the development of 
immunocompetence in the infant (66). Also, apart from immune cells, other cell types have 
been recognized in human milk including  epithelial cells, myoepithelial cells, lactocytes and 
stem cells (64).  
CYTOKINES 
Cytokines are proteins released by cells that exert actions on either the cytokine-producing 
cell or on other target cells (67). As cytokines contribute to the organization,  development 
and function of the immune system they are thus important mediators and regulators of 
inflammatory responses (68).  
The most abundant cytokine in human milk is transforming growth factor- ß known to 
regulate inflammation and to prevent allergy by inducing tolerance in the gastrointestinal tract 
(69).  
Interleukin-10 inhibits the production of pro-inflammatory cytokines and is thought to be 
important for the homeostasis of the intestinal barrier and for the regulation of immune 
responses to foreign antigens (70). 
Interleukin-6 is thought to play an important role for the development and differentiation of 
secretory IgA producing cells in the mammary gland (see below) (71).  
The role of pro-inflammatory cytokines in human milk is still under investigation but it is 
believed that interleukin-1 and interferon- γ may affect the production of secretory IgA and 
other cytokines by the mammary gland (68).   
IMMUNOGLOBULINS 
Immunoglobulins, also known as antibodies, are proteins produced by plasma cells. They 
serve an important role in the immune response by recognizing and binding to particular 
antigens and aiding in their destruction. Antibodies can occur in two physical forms; a soluble 
form that is secreted from the cell into a body fluid or a membrane-bound form that act as a 
receptor on the surface of B-cells.  
In human milk the most abundant immunoglobulin is secretory IgA (45). High concentrations 
of the protein can be found in colostrum (up to 5 mg/mL) decreasing to about 1 mg/mL in 
mature milk (48). Some studies have found a higher concentration of secretory IgA in 
preterm milk than term milk (47,72); still lower concentrations were found in infants born < 
30 weeks of gestation compared to older preterm and term infants in one study (73). The 
secretory IgA antibodies prevent microbes from attaching to mucosal surfaces, especially the 
gut. In that way, maternal secretory IgA antibodies against bacterial, viral and fungal 
pathogens in human milk is transferred to the infant via the entero-mammary pathway, 
boosting the immature immune system of the newborn with the acquired immunity of the 
mother (74) . As the neonate is deficient in secretory IgA in early life, human milk intake of 
the protein provides an important immunological protection to the newborn infant (48).  
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2.1.3.3.5 OLIGOSACCHARIDES 
Oligosaccharides are carbohydrates composed of a few units of single carbohydrates. 
Oligosaccharides are an abundant component of human milk found at concentrations ranging 
from 5-23 g/L (75). Levels of oligosaccharides are higher preterm milk than in term milk and 
decrease during the first 4 months of lactation (76,77). Oligosaccharides have an important 
role in establishing the gut flora of infants passing undigested to the colon part of the 
intestinal tract and promoting the growth of Bifidobacteria and Bacteroides (78). 
Additionally, human milk oligosaccharides prevent several bacteria and viruses from 
adhering to the epithelium of the gastrointestinal tract (75).  
2.1.3.3.6 LACTOFERRIN 
Lactoferrin is a potent multifunctional protein that is abundant in human milk; it is present in 
mature human milk in concentrations of 1.5-4 mg/ml and in colostrum at 8 mg/ml (79). In 
preterm milk, the proportion of lactoferrin relative to total protein is higher than in term milk 
(80). Lactoferrin has antimicrobial properties; it binds to iron and limits the ability of 
pathogens to grow (45) and it acts together with lysozyme in the stomach to kill gram 
positive and gram negative bacteria (81). In addition, lactoferricin, a peptide produced by 
proteolysis  of lactoferrin in acidic milieus, disrupts the cell membrane of gram negative 
bacteria (49). In the small intestine, apart from preventing the adhesion of pathogens to the 
epithelium, lactoferrin promotes proliferation and differentiation of  intestinal epithelial cells, 
initiates apoptosis of infected intestinal epithelial cells, reduces inflammatory cytokine 
production and stimulates the growth of commensal bacteria (49,81).  
2.1.3.4 The composition of preterm human milk  
The composition of preterm human milk differs from that of term milk with higher 
concentrations of many nutritional and bioactive components. These compositional 
differences are most pronounced during the first weeks of lactation (82). Energy, 
carbohydrate, protein and fat amounts are higher in preterm milk than in term milk that may 
reflect a compensatory lactating mechanism in the mother to fulfill the increased nutrient 
needs of the premature infant (82). The differences are most pronounced for protein and fat in 
the most preterm infants (26,83). Preterm milk contains higher concentrations of lysozyme, 
lactoferrin, secretory IgA and milk cells compared to term milk, providing  additional 
immune protection to the preterm infant (46,47,65,72). Furthermore, preterm milk contains 
higher levels of EGF and oligosaccharide important for the maturation of the intestinal 
mucosa and the establishment of the gut flora (50,84). 
Although human milk is considered the best nutrition for the preterm infant, due to its many 
beneficial effects (see below), it does not bring about the specific nutritional needs of the 
premature infant. The human milk fed preterm infant therefore requires nutrient 
supplementation to ensure nutritional adequacy to promote growth and development and to 
prevent nutritional disorders, such as metabolic bone disease and anemia (44,85,86). 
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2.1.4 Benefits of human milk feedings 
Numerous beneficial effects of human milk have been demonstrated for the newborn infant, 
both the infant born at term and for the infant born preterm.  
2.1.4.1 Reduction of morbidity 
2.1.4.1.1 Short-term morbidity 
Breastfeeding protects against respiratory infections, gastrointestinal infections, asthma, 
eczema and atopic dermatitis in infanthood (1). In preterm infants, human milk protects 
against neonatal bacterial infection, necrotizing enterocolitis (NEC) and ROP (87–89). Also, 
it precipitates full enteral feeding, promotes earlier discharge and reduces the rate of  hospital 
readmissions in the first year after discharge (90–92). 
2.1.4.1.2 Long-term morbidity 
Infants with a history of breastfeeding have a reduced risk of  obesity and diabetes mellitus 
(93,94). Additionally, infants that are breastfed at the time of gluten exposure have a 
decreased risk developing celiac disease (95). Furthermore, there is strong evidence that 
prolonged exclusive breastfeeding has beneficial effect on the cognitive development in 
children (48,96). 
In the preterm infant, human milk positively affects long-term neurodevelopmental outcome 
(97–99) and skeletal mineralization (100). In addition, human milk decreases risks for high 
blood pressure in the preterm infant (101).  
2.1.4.1 Reduction in mortality 
In the developing countries, where infectious diseases significantly contribute to infant death, 
breastfeeding significantly decreases infant mortality (102,103). However, even in the 
developed countries, where infectious diseases account for a smaller proportion of infant 
mortality, breastfeeding is associated with a reduced risk for post-neonatal death (104). In the 
developed world, a considerate proportion of infant mortality can be attributed to sudden 
infant death syndrome (SIDS) that can be protected by breastfeeding (105,106). 
2.1.5 Risks of human milk feedings 
There are a few conditions and circumstances where breastfeeding or feedings of human milk 
is considered contraindicated.  
2.1.5.1 Pathogens in human milk 
There are several possible transmission routes for pathogens from the infected mother to the 
breastfed infant; the infant can be infected by respiratory secretions and droplets, via direct 
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contact with lesions in the nipple or the skin of the breast or through breast milk (107). 
Several known pathogens can be transmitted through maternal breast milk.  
2.1.5.1.1 Viral pathogens 
Human T-lymphotropic virus (HTLV) type I , associated with an increased risk for T-cell 
leukemia/lymphoma after early life infection, can be transmitted through breast milk (108). 
Infection with HTLV type I and HTLV type II both have been associated to the development 
of neurological diseases (109). Mothers positive for HTLV type I or II should be advised not 
to breastfeed or to give expressed milk to their infants (107). 
Human immunodeficiency virus (HIV) can be transmitted through breast milk and in the 
industrialized world, HIV infection in the mother is a recognized contraindication for 
breastfeeding. In developing countries however, the risk of malnutrition and infectious 
diseases in non-breastfed infant are thought to outweigh the risk of HIV infection from 
human milk (1). 
Transmission of Hepatitis B virus (HBV) occurs through breast milk. However, if infants of 
HBV surface antigen positive mothers are given hepatitis B immunoglobulin and HBV 
vaccine at birth, HBV transmission is prevented (107).  
Although Hepatitis C virus (HCV) has been detected in low levels in breast milk, HCV 
infection through breast milk has not been proven, and transmission of infection seems 
similar in formula-fed and breast-fed infants of Hepatitis C positive mothers (107,110,111). 
Human cytomegalovirus (CMV) is excreted in breast milk by the majority of breastfeeding 
carrier mothers (112). Whereas breast milk acquired CMV infection is usually asymptomatic 
in term infants, very preterm infants may develop severe clinical manifestations at the time of 
CMV transmission (113–115). For this reason a current debate is ongoing whether to treat 
maternal milk before feeding it  to very preterm infants to reduce the risk of CMV 
transmission (see below).  
2.1.5.1.2 Bacterial and fungal pathogens 
The transmission of bacterial infections from mother to infant through breast milk is rare. 
However, if the mother has a severe contagious infection such as Neisseria gonorrhea, 
Haemophilus influensae, Group B streptococcus or Staphylococcus aureus, breastfeeding 
should be stopped temporarily whereas a longer period of abstinence for breastfeeding is 
required for infection such as Borrelia burgdoferi, Treponema pallidum and Mycobacterium 
tuberculosis (117).  
Candida fungi can be transmitted from the maternal skin to the oral mucosa of the infant, 
particularly in mothers with Candida mastitis (118) . In the healthy term infant breastfeeding 
can be continued during fungal treatment of the mother-infant dyad (119).  
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2.1.5.2 Maternal medications, smoking and alcohol use 
Some maternal medications may induce a risk of drug exposure to the infant through breast 
milk. Mothers medicating with amphetamines, ergotamines, statins and chemotherapy agents 
are generally advised against breastfeeding.  Likewise, milk from mothers abusing 
phencyclidine, cocaine and cannabis may negatively affect long-term neurobehavioral 
development in the infant and is contraindicated (1). 
Alcohol intake affects oxytocin and prolactin release and decreases milk output in lactating 
mothers; therefore limited ingestion of alcoholic beverages is recommended for breastfeeding 
mothers (1,120). 
Maternal smoking while breastfeeding is discouraged as smoking decreases milk volumes 
(121,122) and postnatal maternal smoking increases the risk for sudden infant death 
syndrome and respiratory allergy (1,123,124). 
2.1.5.3 Infant metabolic diseases  
Infants with  diseases that alter metabolism of certain nutrients may need to be nourished 
partly or exclusively with special modified formulas (41).  
For instance, in classic galactosemia, the infant is unable to metabolize lactose and intake of 
galactose results in multi-organ dysfunction. As human milk contains high amounts of 
lactose, breastfeeding is strictly contraindicated. 
In phenylketonuria, the enzyme that converses phenylalanine to tyrosine is defect,  and 
dietary phenylalanine must be limited to avoid accumulation of abnormal metabolites in the 
tissues; breastfeeding is then alternated with phenylalanine free formula while closely 
monitoring phenylalanine blood levels (125).  
2.1.6 Human milk banking 
The World Health Organization and the United Nations Children’s Fund created a ranking of 
feeding choices for infants in 2002. After breastfeeding the infant or feeding with mother’s 
expressed milk, the choice is use of pasteurized milk from another mother via a milk bank 
(10). 
2.1.6.1 History of human milk banking 
By the early 20
th
 century, when services of wet nurses abated and artificial feedings were still 
lacking, lactating women were encouraged to express extra milk for use in premature and ill 
children. With better technology and improvement in hygienic standards human milk 
donation evolved to a sophisticated system of operational milk banks (126). 
The first operational donor milk bank was established in Vienna in Austria in 1909; shortly 
after that two more were opened in Boston, Massachusetts, USA and in Magdeburg in 
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Germany. At that time, more infants of earlier gestational ages with complicated medical 
conditions were surviving, increasing the interest in human milk banking. German and 
English guidelines for the operation of donor milk banks were designed in 1930, and these 
were expanded and adapted by the American Academy of Pediatrics in 1943. However, in the 
1950s and 1960s, improvement in artificial feedings and the common belief that human milk 
could be replaced by formula led to a decline in milk banking both in Europe and in North 
America (126–128). As the interest in human milk banking again was renewed by the mid-
1970s, raw or pasteurized donor milk was primarily used for medical purposes in preterm 
sick infants (129).   
By the mid-1980s however, concerns regarding the risk of CMV and HIV transmission via 
human milk together led to increased used of specialty preterm formulas decreasing the 
demand of donor milk and closure of  many milk banks (126,128–130). Accordingly, the 
Human Milk Banking Association of North America was founded in 1985 so as to 
standardize donor milk bank operations and establish guidelines to make the use of donor's 
breast milk safe. Recommendations on donor milk practices were first published in 1990 and 
are reviewed and updated annually and have been implemented by many other milk banks 
around the world (130). With increased awareness of the benefits of human milk and the 
safety of  using processed bank milk around the world, corresponding regional and individual 
country organizations for milk banking have been established and in many countries national 
guidelines regarding the use of donor milk and the operation of milk banks have been issued 
(131–134). 
In Sweden the network Milknet was established in 2001 by representatives of neonatal care 
with the purpose to maintain and improve access to donated milk, and to exchange 
experiences in breast milk handling and breast-milk feeding of newborn infants in neonatal 
units. The group formed Swedish national guidelines for use of human milk and milk 
handling that were published in 2008 and in a revised version in 2011 (135). 
2.1.6.2 Donor milk use 
Donor milk is the second choice of feedings for very preterm infants and sick infants with 
feeding intolerance treated in the neonatal intensive care unit. The use of donor milk is 
indicated if the mother is not able to express milk, if the use of maternal milk is 
contraindicated or to supplement the mother's own milk supply (135–137).  
2.1.6.3 Milk donors  
Milk donors come from different backgrounds. Mothers with large milk supplies may wish to 
donate so that their milk is not wasted. Other mothers might choose to express extra milk to 
help infants in need. For instance, mothers of preterm infants might want to contribute to 
saving the life of another preterm infant. Moreover, when mothers have lost an infant, 
banking milk could help contribute to healing process (138).  
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2.1.6.4 Donor milk screening 
In Sweden, mothers that wishes to donate milk are screened according to the Swedish 
national guidelines for human milk and milk handling (135). Before acceptance, mothers 
submit a health declaration including health and risk history. 
Mothers who smoke, use snus, use excess alcohol, or illegal drugs are not allowed as donors. 
Donors should not take any medications; some hormonal substitutions, topical inhalations 
steroids, topical treatment of skin, eyes and nose, gestagen contraceptives and occasional use 
of analgesics are though permitted. Women with a history of intravenous drug abuse, who 
have received an organ or tissue transplantation or a transfusion of blood products or have 
had body-piercing or tattooing for the last 12 months are not considered suitable as donors. 
Neither are women with a hemophiliac sex partner or a partner with suspected HIV, HTLV, 
hepatitis or intravenous drug abuse the last 12 months. Woman with cancer are not recruited 
as donors. Every mother should have a negative blood test for HIV, HTLV, HBV, and HCV 
before donation.  
Donated milk should be cultured and proved to be free of pathogenic bacteria and have a 
content of less than 10,000 colony forming units/mL of Staphylococcus aureus and less than 
100 colony forming units /mL of Enterobacteriaceae. During continued milk donation, 
bacterial testing shall be performed once a month. 
2.1.6.5 Storage and treatment of human milk 
Human milk banks collect, pasteurize, store, and distribute the human milk that has been 
donated. In Sweden donor milk is used primarily for preterm infants and almost all handling 
of donor milk is performed in milk banks stationed in neonatal care units.   
In most milk banks, donated milk is pasteurized prior to its use. The most common heat 
treatment is rapid heating to 62.5°C for 30 minutes i.e. Holder pasteurization (135).  
Holder pasteurization effectively eliminates viruses such as HIV, HTLV and CMV as well as 
most of the common bacterial contaminants (139–141). However, treatment by Holder 
pasteurization has unfavorable effect on many nutritional, bioactive and immunological 
components in the milk. It completely inactivates all human milk cells and reduces the levels 
of sIgA, lactoferrin, lysozyme, IL-10 and EPO (142–144). Likewise, it significantly reduces 
the fat and energy content of the milk and completely inactivates the milk lipases affecting 
the infants’ ability to lipid absorption (139,145–147). In addition, the pasteurization process 
usually includes additional steps of changing containers and freeze-thawing that further 
reduces milk fat content (145,148). 
In Sweden, mother’s own milk is generally given succeedingly, as it is expressed, to avoid 
great variation in nutrient intake. Maternal milk is given either fresh or after freezing and 
defrosting (135). Compared to pasteurization, short-term freezing does not have the same 
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detrimental effects on the immunological and bioactive constituents of human milk (142,149–
151).  
2.2 PRETERM BIRTH 
Worldwide, neonatal mortality is a major cause of death in infancy and childhood (152). In 
the developed countries, preterm birth and low birth weight (LBW) are the leading cause of 
neonatal death and infant death. In addition, prematurity and LBW conduce to more than half 
of all neurodevelopmental and other disabilities in infancy, childhood and adolescence (153).  
2.2.1 Definitions of preterm birth, low birth weight and small for gestational 
age  
In humans, an uncomplicated gestation is 40 weeks long, or 280 days, from the first day of 
the last menstrual period.  
Preterm birth is defined as delivery occurring at less than 37 weeks’ gestational age. Preterm 
birth can further be classified into very preterm birth and extremely preterm birth with 
delivery occurring at gestational age less than 32 weeks and 28 weeks, respectively.  
Low birth weight is defined as a birth weight less than 2500 grams, birth weight less than 
1500 grams as very low birth weight (VLBW) and less than 1000 grams as extremely low 
birth weight (153).     
Infants that have lower birth weights than the 10th centile of the index population’s 
distribution of birth weights by gestation are defined as small for gestational age. These 
infants birth weight lies below the 10th centile of the index population’s distribution of birth 
weights by gestation (154). 
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Figure 5. Categorization of preterm birth, low birth weight and small for gestational age. 
(Adapted from http://en.wikipedia.org/wiki/Small_for_gestational_age, accessed 2015-05-02) 
2.2.2 Epidemiology of preterm birth  
According to the World Health Organization, the global rate of preterm births in 2010 was 
11%. The rate of preterm births varies, low-income countries have higher rates on average 
than high-income countries;  estimated rates vary from 5% in many Northern European 
countries to 18% in Malawi (155). Consistent with data from the The National Board of 
Health and Welfare in Sweden, 6% of all deliveries in 2013 in Sweden were preterm births; 
of these 1% were very preterm deliveries before 32 weeks of gestation (156). 
The rate of preterm birth is increasing in most industrialized countries around the world. In 
some countries an increase in preterm births occurring at 32 to 37 weeks is recognized (155). 
In addition, with advances in perinatal medicine even the most immature preterm infants can 
be saved. In Sweden from 1990 to 1992, the infant mortality (0-1 year) of  EPIs born at 23 
and 24 weeks were 92% and 72%, respectively  (157). From 2004 to 2007, the corresponding 
numbers were 48% and 33% (158).  
Likewise, the increased number of indicated preterm deliveries of artificially conceived 
pregnancies are important contributors to increased premature birth rates (159).  
2.2.3 Causes of preterm birth  
Causes of preterm birth can be divided into: 1) indicated preterm labor when delivery is 
brought about for maternal or fetal indications and 2) spontaneous preterm labor that follow 
spontaneous preterm labor with intact membranes or preterm premature rupture of the 
membranes (PPROM) (159). 
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Spontaneous preterm labor is defined as regular contractions accompanied by cervical change 
at less than 37 weeks of gestation.  
PPROM is defined as spontaneous rupture of the membrane at less than 37 weeks’ gestation 
at least 1 hour before the onset of contractions. 
Approximately 30-35% of preterm deliveries are indicated whereas 40-45% follow 
spontaneous preterm labor and 25-30% follow PPROM (159).  
Common reasons for indicated preterm delivery are pre-eclampsia or eclampsia in the mother 
or fetal intrauterine growth restriction (159). Spontaneous preterm labor can be initiated by 
various conditions including inflammation/infection, uteroplacental ischemia or hemorrhage, 
uterine overdistension, cervical disease, stress, endocrine disorders and other 
immunologically mediated processes (160). It is thought to be a multifactorial process where 
a number of risk factors, often associated to systemic inflammation, interact leading to 
preterm delivery or PPROM (159). 
Some of the recognized risk factors for preterm labor are listed in table 2.  
TABLE 2. Risk factors for preterm delivery (Adapted from De Bonis et al. Neonatology 2012 
(160)) 
Risk factors for preterm delivery 
Preconceptional 
- Socio-economic characteristics 
- Previous preterm delivery 
- Interval between pregnancies 
- Nutritional status 
 
Maternal disorders 
- Systematic diseases 
- Local or systemic infections 
- Previous uterine surgery 
 
Pregnacy-associated risk factors 
- Multiple pregnancy 
- Intrauterine infection 
- Vaginal bleeding 
- Bacterial vaginosis 
- Cervical shortening and insufficiency 
 
2.2.4 Prognosis after preterm birth 
2.2.4.1 Preterm mortality 
In Sweden, the overall neonatal mortality (day 1-28 of life) in preterm infants has 
sequentially decreased from 1973 to 2013 with the most pronounced reduction in infants born 
before 33 weeks of gestation (156). 
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Figure 6.  Decrease in neonatal mortality in preterm infants in Sweden from 1973 to 2013.  
(The National Board of Health and Welfare in Sweden, 2014 (156)) 
Both early neonatal death rate (day 0-6 of life) and late neonatal death rate (day 7-28 of life) 
increase inversely to gestational age in preterm infants.   
In Sweden, early neonatal death for infants born at 22- 24 weeks of gestation 2004 to 2013 
was 31%, decreasing to 9% in infants born at 25 to 26 weeks and to 5% in infants 27 to 28 
weeks of gestation, respectively. Corresponding numbers for late neonatal deaths were 9%, 
4% and 2%. Early neonatal death rate of all neonates was 0.12% during the time period late 
neonatal death rate was 0.04% (156). 
2.2.4.2 Preterm morbidity 
Due to the increased rate of preterm births and with the medical and technological advances 
increasing survival of the most preterm infants, preterm births are becoming a significant 
health problem in the developed countries (161,162).  
Preterm birth causes injuries to many organ systems not yet prepared for the extra-uterine 
environment which result in the many complications of prematurity. Consequently, neonatal 
morbidities occur most frequently in the most preterm survivors due to the immaturity of 
their organ systems combined with prolonged hospital stays (163). 
Although many preterm infants with major neonatal morbidities develop normally, neonatal 
morbidities are associated with high mortality rates and later adverse health, growth, and 
neurodevelopmental outcomes (161,164) 
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2.2.4.2.1 Major morbidities  
RESPIRATORY DISTRESS SYNDROME 
Respiratory distress syndrome (RDS) is an acute respiratory illness due to lack of surfactant, 
a substance produced after approximately 30-32 weeks of gestation that helps keep the air 
sacs (alveoli) open (165). The incidence of RDS increases with decreasing gestational age; 
about 5% of near-term infants are affected, 30% of infants of gestational age less than 30 
gestational weeks and 60% of infants born before 28 weeks of gestation. The incidence and 
severity of RDS can be reduced by maternal administration of glucocorticoids prenatally to 
increase fetal lung maturity (166). After delivery, exogenous surfactant provided into the 
lungs improves lung function and decreases the risk of later chronic lung disease (see below) 
(167). 
BRONCHOPULMONARY DYSPLASIA/CHRONIC LUNG DISEASE 
Chronic lung disease, or bronchopulmonary dysplasia (BPD),  is defined as a requirement for 
oxygen at 36 weeks of postmenstrual age (168). 
Classically, before the introduction of antenatal corticosteroid and postnatal surfactant 
therapy, BPD occurred in preterm infants who had been treated with high ventilation 
pressures and oxygen concentrations for severe RDS. The condition was characterized by 
airway inflammation, fibrosis and smooth muscle hypertrophy (169). With advances in 
neonatal care a new disease entity developed where lung development is arrested before 
alveolarization resulting in lungs with larger but fewer alveoli. Likewise, impaired 
vasculogenesis results in a smaller vascular bed with increased vascular tone and reactivity 
(169). A number of factors have been implicated to contribute to the abnormal lung 
development; neonatal sepsis, patent ductus arteriosus (PDA), mechanical ventilation, oxygen 
therapy and possibly fetal response to chorioamnionitis and colonization by the bacteria 
Ureoplasma (169). 
BPD results in chronic respiratory insufficiency with prolonged oxygen dependence. Infants 
with BPD have reactive airways, an increased vulnerability to respiratory infections and 
nutritional and fluid problems due to increased metabolic needs and fluid sensibility 
(165,170). BPD increases the risk of other neonatal complications such as patent ductus 
arteriosus (PDA), sepsis, intraventricular hemorrhage (IVH), ROP and death (170).  
The risk to develop BPD is inversely related to both birthweight and gestational age at birth. 
In Sweden during 2004–2007 the incidence of BPD in infants born before 27 gestational 
weeks was 73%; 61%, 75%, 81%, 88% and 100% for gestational ages 26, 25, 24, 23 and 22, 
respectively (164).  
Acknowledged measures to reduce the incidence of BPD include non-invasive ventilation 
and careful oxygen delivery whereas pharmacologic treatments comprise prophylactic 
surfactant therapy, methylxantines and vitamin A supplementation (171).  
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Today, BPD is the most common chronic respiratory disease in infancy, causing reduced lung 
function through childhood and into adult life (172). Furthermore, children with BPD born 
very preterm have an increased risk for cognitive, educational and behavioral impairments 
compared to very preterm infants without BPD (173).  
PATENT DUCTUS ARTERIOSUS 
Ductus arteriosus is a temporary fetal blood vessel between the pulmonary artery and aorta 
allowing fetal blood to bypass circulation to the lungs in utero. The ductus arteriosus 
normally closes after birth, when air enters the lungs and the lungs expand, redirecting the 
blood to the lungs.  
In preterm infants, the duct may not close properly, shunting too much blood to the lungs 
which can lead to heart failure and reduced blood flow to vital body organs (165).   
 
 
Figure 7. The great arteries and the ductus arteriosus (Schneider DJ 2012 (174)) 
The incidence of PDA in preterm infants increases almost linearly with decreasing gestational 
age, or circa 9% for each week of gestation (175). 
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Figure 8.  The incidence of PDA increases with decreasing gestational age. (Adapted from Hajj 
H 2012 (175)) 
A PDA may close spontaneously, or, it can complicate a preterm infant’s clinical course with 
an increased the risks for neonatal complications such as IVH, NEC, BPD or death (165). 
PDA closes spontaneously within a few days in the majority of the more mature preterm 
infants. In extremely low birthweight infants however, the rate of spontaneous closer is only 
33% within the first week of life (176). 
Current treatment approaches to a PDA today include pharmacologic treatment with 
nonselective inhibitors of cyclooxygenase (Indometacin or Ibuprofen) or surgical ligation. 
However, as spontaneous closure occurs in a substantial proportion of preterm  infants 
randomized controlled trials to evaluate the risk/benefit of these treatment are lacking and 
these treatment options are currently debated (177,178).  
INTRAVENTRICULAR HEMORRHAGE AND PERIVENTRICULAR 
LEUKOMALACIA  
In preterm infants, the incomplete formation of the central nervous system renders it 
vulnerable to injury, especially the highly vascular germinal matrix and the white matter 
around the ventricles that have difficulties with auto-regulation of cerebral blood flow (165).  
Brain injury constitutes a main complication in the perinatal period with  long-term 
consequences as early injury can interrupt normal brain maturation with the risk of 
subsequent neurodevelopmental disabilities (179). 
2.2.4.2.1.1.1 INTRAVENTRICULAR HEMORRHAGE 
IVH is a major complication of preterm birth. Massive IVH may result in death from 
hypovolemic shock, while large hemorrhages may result in severe disability in the affected 
infant (180). 
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IVH is a complex, developmental disorder where multiple environmental and genetic factors 
interact (181).  IVH usually occurs in infants born before 32 weeks of gestation and the 
incidence is inversely related to gestational age (182). In the national Swedish EXPRESS 
study, 10% of infants born before 27 weeks of gestation had severe IVH (grade 3 or more, 
see classification below) (164). Even if IVH can occur in utero, IVH is usually an early 
postnatal event ensuing within the first 72 hours after birth (165,180). 
IVH originates from the capillaries of the germinal matrix just below the ventricles. This sub-
ependymal germinal matrix, rich in immature vessels poorly supported by connective tissue, 
is vulnerable to fluctuations in cerebral blood flow and swings in intra-thoracic and venous 
pressure that occurs with severe respiratory problems in the preterm infant. Subsequent to 
bleeding in the subependymal germinal matrix, blood filling the lateral ventricles may lead to 
ventricle dilatation (165,180).  
IVH is graded according to Papile’s classification; Grade I is confined to the sub-ependymal 
germinal matrix with no blood clot in the lumen, Grade II is defined by the presence of blood 
within the ventricular lumen but without ventricular dilatation, Grade III consists of IVH with 
ventricular dilatation, and Grade IV is IVH accompanied by parenchymal hemorrhagic 
infarction (183). 
 
Figure 9. IVH grading according to Papile (Köksal V 2010 (184)) 
Management of IVH encompasses:  prophylactic care by minimal handling of the EPT 
infants; screening for symptoms of IVH; supportive care with correction of underlying 
medical disturbances, such as blood pressure, respiratory status and coagulopathies, which 
might influence progression of IVH; and treatment of the ensuing complications such as 
seizures and post-hemorrhagic hydrocephalus (182).   
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The outcome of IVH depends on gestational age and the severity of the bleeding. Short-term, 
5 to 10% of preterm infants with Grade III or IV IVH suffer seizures in the neonatal period 
and up to 50% develop post-hemorrhagic hydrocephalus (180) and the overall mortality is 
higher than in gestational age-matched infants without IVH (182).  
In the long-term, IVH conveys an increased risk of  cerebral palsy, visual impairment and 
delayed psychomotor and mental development with the risk for sequelae inversely related to 
the gestational age of the infant and correlating to the grade of bleeding (185).  
2.2.4.2.1.1.2 PERIVENTRICULAR LEUKOMALACIA 
Periventricular leukomalacia (PVL) is the predominant brain injury underlying neurologic 
morbidity in preterm infant; it is the main cause of cerebral palsy and cognitive impairment in 
these infants (186). Using magnetic resonance imaging, some degree of cerebral white matter 
injury can be detected in at least 50% of VLBW infants (187) .  
PVL is caused by white matter necrosis due to ischemia-reperfusion injury in the cerebral 
artery watershed area and is expressed as either focal periventricular necrosis with subsequent 
development of cysts or diffuse cerebral white matter injury (163,188). PVL is highly 
correlated with prematurity. Other contributing factors include chorioamnionitis, neonatal 
hypocarbia and hypotension (188).  
There are no effective treatments for periventricular white matter damage, though promising 
neuroprotective strategies are emerging (189). Adequate supportive neonatal care contributes  
to improve the final neurological outcome (190).  
NECROTIZING ENTEROCOLITIS 
NEC is an  acute inflammatory necrosis of the intestinal tract primarily affecting preterm 
VLBW infants (191). As a major cause of morbidity and mortality in neonates it has become 
one of the most dreaded diseases in neonatal intensive care units (192).  The incidence of 
NEC is increasing as a result of advances in neonatal care and shows a clear, inverse 
relationship with birth weight and gestational age (193,194). NEC manifests in 7 to 11 % of 
infants born weighing less than 1500 g (195); about half of these infants will require surgery 
of which 30% will not survive (196).  
NEC is a multifactorial illness with an incomplete understood pathogenesis. The combination 
of bowel immaturity, abnormal pathogenic colonization of the bowel , enteral feedings and 
intestinal ischemia are thought to provoke an aggravated intestinal inflammatory response 
that lead to damage of gut epithelium, translocation of intraluminal contents and induction of 
a systemic inflammation response (191,197).  
Currently acknowledged risk factors include formula feedings, prolonged empirical antibiotic 
treatment and the use of acid blockade (198).  
The use of human milk is of major importance in the prevention of NEC (198). Human milk 
reduces the incidence and severity of NEC with some studies demonstrating  a dose-
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dependent effect (199–201). The protective effect of human milk can be attributed to its 
content of  bioactive factors; these are of importance for the development of the infant´s gut 
mucosa, the establishment of a favorable  intestinal microbial ecology and due to their anti-
pathogenic and immunomodulary properties (2,202). Standardized feeding regimens, 
minimized antibiotic and acid blockade treatment are additional protective measures against 
NEC (198). Among other proposed preventive strategies against NEC are the use of 
probiotics and oral lactoferrin; however, these alternatives need more study (203,204).     
The classical manifestations of NEC in a preterm infant are abdominal distension, feeding 
intolerance and bloody stools presenting at about 29-32 weeks of postmenstrual age. The 
progress of the disease may be rapid, succeeding from subtle signs to abdominal 
discoloration, intestinal perforation and peritonitis, advancing to systemic hypotension 
requiring intensive medical and frequently surgical support (205).  
In the field of neonatology and pediatric surgery, Bells staging is used to gauge the severity 
of NEC (206):  
TABLE 3. Modified Bell´s staging for NEC (Adapted from Gordon 2007 Journal of 
Perinatology (206)) 
Review of 
Bell's stages 
Clinical findings Radiographic findings Gastrointestinal findings 
Stage I Apnea and bradycardia, 
temperature instability 
Normal gas pattern or mild 
ileus 
Gastric residuals, occult 
blood in stool, mild 
abdominal distention 
Stage II A Apnea and bradycardia, 
temperature instability 
Ileus gas pattern with one or 
more dilated loops and focal 
pneumatosis 
Grossly bloody stools, 
prominent abdominal 
distention, absent bowel 
sounds 
Stage II B Thrombocytopenia and mild 
metabolic acidosis 
Widespread pneumatosis, 
ascites, portal-venous gas 
Abdominal wall edema with 
palpable loops and 
tenderness 
Stage III A Mixed acidosis, oliguria, 
hypotension, coagulopathy 
Prominent bowel loops, 
worsening ascites, no free air 
Worsening wall edema, 
erythema and induration 
Stage III B Shock, deterioration in 
laboratory values and vital 
signs 
Pneumoperitoneum Perforated bowel 
Today, NEC is treated either by medical interventions or, in case of deteriorating status with 
intestinal perforation, surgery as well. Apart from intravenous antibiotics, medical 
interventions include abdominal decompression, bowel rest and intravenous fluid 
resuscitation whereas surgical procedures encompass drain placement or exploratory 
laparotomy with resection of diseased bowel (207).  
Short-term complications of NEC survivors comprise recurrent disease, strictures and stoma 
complications. The most common long-term gastrointestinal complication is short bowel 
syndrome, affecting about one-fourth of NEC survivors. Abnormal growth may occur, 
especially in those children with short bowel syndrome. Likewise, infants surviving NEC 
have an increased risk for neurodevelopmental dysfunction (207). 
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RETINOPATHY OF PREMATURITY 
ROP is a leading cause of visual impairment and blindness among preterm infants (208)  It is 
a neovascular retinal disorder with multifactorial etiology. Preterm infants have incompletely 
vascularized retinas with a peripheral avascular zone. As the infant matures, the 
nonvascularized retina becomes increasingly metabolically active, leading to tissue hypoxia. 
Hypoxia stimulates up-regulation of proangiogenic growth factors such as VEGF and EPO 
which can lead to uncontrolled vascular growth into the vitreous (209).  
Multiple risk factors have been suggested in the genesis of ROP. Prematurity, low birth 
weight and postnatal oxygenation are recognized risk factors (62,210).  Likewise, low early-
postnatal serum IGF-1 concentrations increase later risk of ROP. In utero, IGF-1 
concentrations increase with length of gestation; after birth, IGF-1 levels are nutrition 
dependent and decrease with starvation, infection and stress. Preventive postnatal measures 
against ROP thus comprise careful oxygenation, and provision of adequate nutrition and 
treatment of infections (62,211).  
ROP is classified according to the international classification of ROP (212). Staging indicates 
the severity of the disease; stage 1-2 comprise mild ROP and stages 3-5 severe ROP. Stage 1 
is defined as a distinct line between the vascularized and avascularized regions of the retina. 
Stage 2 occurs when the line noted in Stage 1 gains both depth and height. When the blood 
vessels extend into the vitreous, it is classified as Stage 3. Stage 4 is defined as partial retinal 
detachment; Stage 5 is total retinal detachment (213). 
In a national Swedish study conducted 2008 to 2009 and including 1784 infants less than 32 
weeks of gestation, ROP was found in 25.1% of infants; among these 8.5% had severe ROP 
(214). Comparable, the reported incidence of severe ROP in infants less than 27 weeks of 
gestation in the Swedish express study was 34% (164).   
Early detection of ROP in preterm infants is ensued by appropriate screening protocols during 
the first weeks of life. Severe ROP is managed with ablation of the non-vascularized retina 
with trans-pupillary laser treatment thereby avoiding aberrant preretinal neovascularization 
(62). A new promising impending approach against ROP in clinical practice is intravitreal 
anti-VEGT therapy; however the safety profile of this treatment must be better elucidated as 
these drugs may interfere with vasculature development elsewhere in the body (215,216). 
Apart from visual loss and blindness, ROP is associated with other eye problems, such as 
strabismus, myopia and astigmatic refractive errors, prompting the need of continuous follow 
up in these infants (209). 
INFECTIONS 
In low birth weight and preterm infants neonatal infection is a significant cause of mortality 
and short and long-term morbidity. The pro-inflammatory state associated with infection may 
interrupt developmentally regulated processes involving the central nervous and respiratory 
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systems resulting in an increased risk for death, chronic lung disease, and adverse 
neurodevelopmental outcome (217).  
Neonatal infections can have an early onset within 72 hours of birth or a late onset when 
occurring after the first 72 hours. Septicemia accounts for the majority of all infections (45-
55%) preceding low respiratory tract infections (16-30%) and urinary infections (8-18%). 
Early onset sepsis is often related to maternal pregnancy complications and usually involves 
pathogenic organism of the maternal genitourinary tract whereas late onset sepsis (LOS) is 
usually caused by nosocomial or environmental pathogens (218).   
Nosocomial infection rate is inversely related to birth weight and gestational age (219). In a 
report from The National Institute of Child Health and Human Development Neonatal 
Research Network by Stoll et al., the incidence of culture proven LOS in VLBW infants over 
a 2 year period (1998-2000) was 21% ; 46% for infants less than 25 weeks’ gestation, 29% 
for infants 25 to 28 weeks’ gestation, and 10% for infants 29 to 32 weeks’ gestation (220).  
Very preterm infants are susceptible to infections due to naive immune systems, defective 
regulation in immune homeostasis and lack of acquired maternal immune factors (221).  
While infants born at term are protected by maternal antibodies, transferred to them through 
the placenta, preterm infants may lack maternal antibodies, which largely occur during the 
third trimester of gestation (221). Furthermore, ill preterm infants undergo medical 
interventions such as mechanical ventilation, intravenous lines and drains that interfere with 
the body's protective mucosal and epithelial barriers (222).  
Postnatal infections in preterm infants can be acquired through their immature skin, lungs, or 
gastrointestinal tract, which lack fully developed immunoprotective functions. Due to their 
immature immune system, they have difficulty confining these infections to where they arise 
so sepsis frequently develops (165).  
Apart from low birth weight and prematurity, risk factors for early onset sepsis include 
maternal group B streptococcal colonization, maternal intraamnionic infection and prolonged 
rupture of membranes (> 18 hours) (223). Risk factors for LOS comprise postnatal use of 
steroids and H2 antagonists, poor hand hygiene, previous antimicrobial exposure and central 
venous catheters (218,224).To the contrary, the use of human milk feedings and oral 
administration of oral lactoferrin, a component of breast milk (see above), have protective 
effect against neonatal sepsis in preterm infants (87,203)  
Clinical manifestations of neonatal infection can vary. Symptoms can present very subtly and 
progress gradually or a rapid deterioration with sudden collapse can occur. In general, 
infected neonates present with systemic signs such as recurrent apneas that may necessitate 
mechanical ventilation. Hypotension, shock, renal and hepatic dysfunction, coagulopathy, 
thrombocytopenia, glucose dysregulation and seizures can also be accompanying features  
(221). 
The most prevalent pathogens of neonatal infection are listed in table 4.  
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Table 4. Important organisms presenting as neonatal sepsis (Ghazal P 2013 (221)). 
 
Neonatal infections require prompt treatment with antibacterial, antiviral or antifungals drugs 
depending on the suspected pathological agent (223). Currently available strategies to prevent 
neonatal infections include policies related to neonatal management, and the use of 
drugs/bioactive substances that may be helpful in preventing diseases caused by specific 
pathogens. These include hand-hygiene, prevention of central-line associated blood stream 
infections, skin care, early feedings with human milk, appropriate use of drugs for therapy 
and prophylaxis and restricted use of steroids and antacids (225,226). 
2.2.4.2.2 Long-term complications  
Infants born preterm are at increased risk of long-term developmental, behavioral and health 
problems. Although these sequelae are most common and most serious for infants born 
extremely  preterm, they also apply to infants with minor degrees of prematurity (227). 
Encountered problems include cognitive and motor impairments, asthma, visual and hearing 
impairments, behavior disturbances, impaired growth, osteopenia and reduced bone mass 
(227–229). Furthermore, preterm birth is an important independent risk factor for the 
development of cardiometabolic disease and renal disease in later life (230,231).  
On the other hand, according to available studies, the majority of infants born preterm live an 
independent productive life, and, by their own rating, their life has a more or less the same 
quality as their term born peers (232,233). 
2.2.5 Human milk in preterm infant feeding 
As described earlier, the benefits of human milk in the management of preterm infants are 
well recognized, and as such, all preterm infants are recommended to receive human milk (1). 
Furthermore, the provision of mother’s own milk to her infant has emotional bearing for the 
mother, allowing her a distinct role in the intensive care of her infant (234). However, the 
route to successful lactation often presents unique challenges to mothers of premature infants, 
including establishing and maintaining a milk supply and transitioning from gavage feeding 
to breastfeeding (235). 
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2.2.5.1 Infant factors affecting lactation 
Preterm infants, especially very preterm infants, may not have fully developed skills at birth 
to feed independently at the breast (236). In preterm infants, the emergence of sucking 
competence has been observed as early as 27 weeks postconceptional age (237). However, in 
the most preterm infants and the transition time from starting suckling feedings to exclusive 
suckle feeding is longer than in more mature preterm infants. Likewise, neonatal conditions 
affecting the respiratory and circulatory systems that are more common in the most preterm 
infants, can further delay the accomplishment of full oral feedings (236). Thus, until the 
infant can take oral feedings, mothers need to pump or express breast milk that is thereafter 
stored and fed to the infants by nasogastric tube (238,239). 
2.2.5.2 Maternal factors affecting lactation 
Mothers of preterm infants are at greater risk for lactation failure after birth than mothers of 
term infants (240). This is especially true of mothers giving birth at extremely preterm 
gestational ages, due to the earlier stage of breast development at parturition since the 
mammary epithelium may not be sufficiently prepared by the pregnancy hormones to 
synthesize milk efficiently (85). Furthermore, research has shown a significant delay in the 
onset of lactogenesis II among mothers of EPIs (241). 
2.2.5.3 Optimizing lactation success 
Early, frequent and effective milk expression is crucial to the initiation of preterm lactation. A 
positive relationship has been shown between milk volume and the time point of initiation of 
pumping after delivery and the frequency and duration of pumping (242–244). In order to 
keep up with the increasing nutritional needs of the infants, mothers should strive at a milk 
volume of 750 ml/day at day 10 postpartum (245).  Early initiation of kangaroo care can 
increase milk volumes and thereby counteract insufficient lactation (246). Oxytocin and the 
prolactin enhancer domperidone may have a role in mothers not responding to these 
interventions, but at present, safety data regarding the use of these galactogouges is missing 
(247). 
2.2.5.4 Donor milk feedings in preterm infants 
Donor milk is primarily used for preterm infants as a supplement to maternal milk feedings 
the first days after delivery until mother’s own milk production is sufficient to fulfill the 
infants’ needs. It is also used if the mother is unable to express milk or if the milk cannot be 
used for medical reasons (135). Compared to formula, donor milk reduces the risk of NEC,  
may protect against BPD and possibly improve feeding tolerance and reduce adolescent risk 
factors for cardiovascular disease (248,249).  
In most neonatal units in Sweden, in order to guarantee optimal nutritional composition of the 
donor milk before feeding it to the preterm infant, nutritional analysis for protein, fat, and 
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carbohydrate contents is performed, with subsequent fortification of the milk according to the 
nutritional content determined by the nutritional analysis (135). 
2.2.5.5 Breastfeeding the preterm infant 
Mothers and their preterm infants often experience difficulties in making the transition from 
expressing milk and gavage feeding to feeding at the breast. Indeed, the initiation rate and 
duration of breastfeeding for preterm infants are lower than for full term infants (235,250). 
However, interventions in the neonatal units such as maternal support and education, 
kangaroo care or skin to skin care, pre-feeding oral stimulation, infant’s nonnutritive sucking 
on the breast, and the avoidance of bottles during the transition process can facilitate the 
transition to breastfeeding (251,252). Regarding the initiation and establishment of 
breastfeeding in the preterm infant, reference is made to the expert group recommendations 
of the Baby-Friendly Hospital Initiative Ten Steps to Successful Breastfeeding into Neonatal 
Intensive Care (253). 
 
 
Figure 10.  A preterm infant being fed human milk by nasogastric tube while skin to skin 
holding. (With permission from the caregivers. Photo by Ann Sofie Ingman.) 
2.3 HUMAN CYTOMEGALOVIRUS (CMV) 
CMV infection is a leading source of congenital infection worldwide and a cause of 
significant morbidity and mortality in immunocompromised patients (254,255). In the 
developed world, it is the most common cause of nonhereditary sensorineural hearing loss 
and an important contributor to developmental delay (255). 
2.3.1 The discovery of CMV 
In the literature, the histopathological changes in tissue typical for CMV were first described 
in 1881 by the German scientist Ribbert who described large unidentifiable cells in kidney 
sections of a stillborn syphilitic infant and also in the parotid glands of other children.  
 
 37 
carbohydrate contents is performed, with subsequent fortification of the milk according to the 
nutritional content determined by the nutritional analysis (135). 
2.2.5.5 Breastfeeding the preterm infant 
Mothers and their preterm infants often experience difficulties in making the transition from 
expressing milk and gavage feeding to feeding at the breast. Indeed, the initiation rate and 
duration of breastfeeding for preterm infants are lower than for full term infants (235,250). 
However, interventions in the neonatal units such as maternal support and education, 
kangaroo care or skin to skin care, pre-feeding oral stimulation, infant’s nonnutritive sucking 
on the breast, and the avoidance of bottles during the transition process can facilitate the 
transition to breastfeeding (251,252). Regarding the initiation and establishment of 
breastfeeding in the preterm infant, reference is made to the expert group recommendations 
of the Baby-Friendly Hospital Initiative Ten Steps to Successful Breastfeeding into Neonatal 
Intensive Care (253). 
 
 
Figure 10.  A preterm infant being fed human milk by nasogastric tube while skin to skin 
holding. (With permission from the caregivers. Photo by Ann Sofie Ingman.) 
2.3 HUMAN CYTOMEGALOVIRUS (CMV) 
CMV infection is a leading source of congenital infection worldwide and a cause of 
significant morbidity and mortality in immunocompromised patients (254,255). In the 
developed world, it is the most common cause of nonhereditary sensorineural hearing loss 
and an important contributor to developmental delay (255). 
2.3.1 The discovery of CMV 
In the literature, the histopathological changes in tissue typical for CMV were first described 
in 1881 by the German scientist Ribbert who described large unidentifiable cells in kidney 
sections of a stillborn syphilitic infant and also in the parotid glands of other children.  
 38 
Shortly thereafter, analogous findings were reported by other scientists, describing protozoan 
like cells in lung, kidney and liver tissue of a luetic fetus that had eccentrically placed nuclei 
containing a “central nuclear body” surrounded by clear halo.  
 
Figure 11. CMV infected cytomegalic cell with intranuclear inclusion with halo. (Ho 2008 (256)) 
Subsequently, in 1921, when similar intranuclear inclusion containing cells were also 
described in lesions of patients infected by herpes zoster, these histopathologic findings were 
thought to be caused by viruses that were related (256).    
In 1950, Wyatt et al. described the disease entity “generalized cytomegalic inclusion disease” 
after the detection of cells with the intranuclear inclusions in tissues of infants that had died 
of a congenial infection characterized by hepatosplenomegaly, petechiae, and intracerebral 
calcification (257). Following that, cytomegalic inclusion disease was diagnosed based on the 
presence of inclusion-bearing cells in the urine of infected infants. 
In 1953, a viruslike particle could be detected with low-resolution electron microscopy in the 
halo around the intranuclear inclusion of a pancreatic cell of a case with cytomegalic 
inclusion disease.  
However, only after the achievement of growing human cells in culture, could the virus 
finally be isolated in by 3 independent research groups; Smith and Rowe et al. in 1956 and by 
Weller et al. in 1957 (258). 
A few years later, the name cytomegalovirus (from the Greek cyto-, "cell", and -megalo-, 
"large") replaced the previous used terms of “cytomegalic inclusion disease virus” or  
“salivary gland virus” (259) .  
2.3.2 The herpes virus family  
CMV belongs to the herpes virus family, or herpesviridae, distinguished by a common virion 
morphology.  The herpesviruses are large viruses (150-200 nm) with double stranded DNA 
enclosed in a core within an icosahedral capsid, protein tegument, and lipid envelope (260).  
 
38 
Shortly thereafter, analogous findings were reported by other scientists, describing protozoan 
like cells in lung, kidney and liver tissue of a luetic fetus that had eccentrically placed nuclei 
containing a “central nuclear body” surrounded by clear halo.  
 
Figure 11. CMV infected cytomegalic cell with intranuclear inclusion with halo. (Ho 2008 (256)) 
Subsequently, in 1921, when similar intranuclear inclusion containing cells were also 
described in lesions of patients infected by herpes zoster, these histopathologic findings were 
thought to be caused by viruses that were related (256).    
In 1950, Wyatt et al. described the disease entity “generalized cytomegalic inclusion disease” 
after the detection of cells with the intranuclear inclusions in tissues of infants that had died 
of a congenial infection characterized by hepatosplenomegaly, petechiae, and intracerebral 
calcification (257). Following that, cytomegalic inclusion disease was diagnosed based on the 
presence of inclusion-bearing cells in the urine of infected infants. 
In 1953, a viruslike particle could be detected with low-resolution electron microscopy in the 
halo around the intranuclear inclusion of a pancreatic cell of a case with cytomegalic 
inclusion disease.  
However, only after the achievement of growing human cells in culture, could the virus 
finally be isolated in by 3 independent research groups; Smith and Rowe et al. in 1956 and by 
Weller et al. in 1957 (258). 
A few years later, the name cytomegalovirus (from the Greek cyto-, "cell", and -megalo-, 
"large") replaced the previous used terms of “cytomegalic inclusion disease virus” or  
“salivary gland virus” (259) .  
2.3.2 The herpes virus family  
CMV belongs to the herpes virus family, or herpesviridae, distinguished by a common virion 
morphology.  The herpesviruses are large viruses (150-200 nm) with double stranded DNA 
enclosed in a core within an icosahedral capsid, protein tegument, and lipid envelope (260).  
  39 
 
 
Figure 12. Morphology of herpesviruses. (Mettenleiter TC 2003(260)) 
Based on their growth characteristics and tissue tropism, herpes viruses are further subdivided 
into three subfamilies. Among the 8 herpesviruses infecting humans, herpes simplex virus 1 
and 2 and varicella virus are neurotropic and belong to the α-subfamily. Ebstein Barr virus 
and and Kaposi’s sarcoma-associated herpesvirus are lympothotropic and have a place in the 
γ-subfamily. CMV and human herpesvirus 6 and 7 belong to the β-subfamily and are able to 
establish infections in many cell types (261). After primary infection, viruses of the herpes 
family persist in a latent state in the host thereby avoiding virus elimination by the immune 
system or host destruction by the infection. As the viruses have coevolved with the human 
host, they have managed to develop an array of strategies to escape the multifaceted antiviral 
immune response in humans (262). 
2.3.3 Epidemiology and transmission 
CMV infection is prevalent in human populations worldwide with a seroprevalence in the 
adult population ranging from 45%-100% (263). CMV seroprevalence is higher in the 
developing countries and increases with age. In the developed countries a higher prevalence 
has been observed among non-whites, immigrants from the developing countries and in the 
lower socioeconomic strata (264).  In a population based serological study conducted in 
Sweden 1973-1982, CMV seroprevalence was 40% in the age group 1-4 years increasing to 
80-100% in the older age groups (265). In a more recent study by Engman et al. performed in 
2003 and 2004, the CMV seroprevalence among 1000 pregnant Swedish women was 72% 
(266). 
CMV can be transmitted via placenta, at delivery via the birth canal, or postnatally through 
intimate contact via infected body fluids, transfusion of blood products or transplantation of 
solid organs from CMV seropositive donors (267). 
After initial acquisition of CMV, the immune system of the host is unable to eliminate the 
virus, leading to a latent infection that can be reactivated at any time when the delicate 
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balance with the host immune system is disrupted. Reactivation from the latent state can be 
silent or cause severe disease in the host for example in the immunosuppressed or critically ill 
patient (268).  
Following primary infection or reactivation from its latent state, CMV can be shed in body 
fluid by the host for months to years thereby promoting further spread of the virus (264).  
2.3.4 Clinical manifestations 
2.3.4.1 Congenital CMV infection 
CMV is the most common cause of human congenital infection with reported prevalence 
ranges globally between 0.3 to 6%, with higher prevalence in the developing countries (269). 
Approximately 10-15% of infants with congenital CMV infection present at birth with 
clinical manifestations, i.e. a systemic congenital CMV disease (270). The clinical symptoms 
derive primarily from organs of the reticulotendothelial system and central nervous system 
and comprise jaundice, hepatosplenomegaly, petechiae, microcephaly, seizures, hypotonia 
and lethargy. The infected newborn is often a growth retarded and prematurely born baby. 
About one third of the most severely affected infants die of hepatic dysfunction, bleeding, 
coagulopathy or secondary bacterial infections (271). Of those infants surviving, the majority 
(50% to 90%) will suffer from later neurological sequelae including mental retardation, 
cerebral palsy, impaired vision and sensorineural hearing loss (264). 
About 85-90% of infants infected by CMV in utero have an asymptomatic congenital CMV 
infection with no overt clinical symptoms at birth. However, approximately 7% to 25% of 
these asymptomatic infants will also develop CNS sequelae, mainly sensorineural hearing 
loss (264). 
Today, congenital CMV infection is the most important cause of sensorineural hearing loss 
during childhood affecting about 10-15% of all infants infected by CMV in utero (271).  
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Figure 13. A newborn infant with systemic congenital CMV disease. This infant presented at 
birth with  disseminated violaceous cutaneous nodules , hepatopathy, thrombocytopenia and 
coagulopathy (Martins 2011 (272)) 
2.3.4.2 CMV infection in the immunocompetent host 
Primary CMV infection is usually clinically silent in the immunocompetent individual but 
can at times cause an acute febrile illness resembling mononucleosis with fever, malaise, 
myalgias, headache, and fatigue. Splenomegaly, hepatomegaly, adenopathy, and rash can 
occur (264,273). Occasionally, CMV infection present in the apparently immunocompetent  
host with similar manifestations as encountered in the immunocompromised host or even 
with life-threatening illness (264,274,275).  
Several medical conditions have been linked to CMV infection in the immunocompetent 
host. CMV has been implicated as a cofactor in the pathogenesis of atherosclerosis and 
coronary heart disease (276,277). The virus has been detected in the bowel of patients with 
inflammatory bowel disease and in patients with plaque psoriasis, rheumatoid arthritis, 
systemic lupus erythematosus and Sjögrens  syndrome (278,279). In addition, CMV has been 
identified in tumors of the colon, breast, prostata and brain; likewise, the virus is frequently 
found in brain metastases of primary breast and colon tumors (280,281). Today, extensive 
research is further evaluating the role of CMV in the genesis of these conditions and if anti 
CMV treatment may improve patient outcome (282). 
2.3.4.3 CMV infection in the immunocompromised host 
CMV infection is a common complication in the care of immunocompromised patients 
resulting from either reactivation of latent virus, reinfection or primary infection. Although 
the infection can be clinically asymptomatic, it can cause life-threatening and debilitating 
disease, especially in the most immunosuppressed patients; recipients of allogeneic stem cell 
transplants, solid organ transplant recipients, patients with AIDS and very low CD4 counts,  
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patients receiving immunosuppressive chemotherapy,  infants with congenital 
immunodeficiency and infants born very prematurely (264).  
In transplant patients, CMV infection is defined as isolation of the virus or detection of 
CMV proteins or nucleic acid in a body fluid or tissue specimen; CMV disease is defined as 
CMV infection accompanied by symptoms and signs of an affected end-organ (283,284). 
CMV can cause a variety of end-organ diseases in immunocompromised patients. Amongst 
allogenic stem cells recipients, the most common clinical presentations of CMV disease are 
gastrointestinal disease and pneumonitis, the latter being a cause of mortality in more than 
50% of patients afflicted (285). 
In solid organ transplant recipients, CMV infection can present as CMV syndrome; an 
acute, systemic, febrile illness with laboratory signs of neutropenia, thrombocytopenia, and 
elevated hepatic transaminases. The CMV infection can also target specific end-organs 
causing pneumonitis, gastrointestinal lesions, hepatitis, retinitis, pancreatitis, myocarditis, 
and rarely, encephalitis or peripheral neuropathy. Furthermore, CMV infection in solid 
organ transplant recipients has been linked to graft rejection, accelerated coronary artery 
atherosclerosis and new-onset diabetes mellitus (264,286). 
An indirect effect attributable to CMV infection in both allogenic stem cells recipients and 
solid organ transplant recipients is an increased risk for opportunistic fungal and bacterial 
infections (264,287). 
Before the use of combined treatment in HIV patients in 1995 with at least three 
antiretroviral drugs of different classes, CMV infection was one of the most important 
opportunistic infections in patients infected by HIV, prevalent in 40% of patients with 
advanced disease. Today the risk of CMV disease chiefly remains in those patients with 
low CD4 cell counts (< 100/ μL). Retinitis is the most common clinical manifestation 
accounting for about 85% of CMV disease followed by gastrointestinal disease accounting 
for about 15% of cases. CMV encephalitis is a rare (<1%) but important manifestation of 
CMV disease in HIV-infected patients with a detrimental outcome if left untreated with a 
nearly 100% mortality rate (288,289).  
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Figure 14. CMV retinitis in a patient with AIDS (Steininger 2006 (288)) 
2.3.4.4 Postnatal CMV infection in the preterm infant 
The most common source of postnatal CMV infection in the preterm infant is maternal 
breast milk (290). CMV is excreted in breast milk of the majority of CMV seropositive 
mothers (116). Nearly half of all infants nursed for a longer period by mothers that have 
been infected by CMV acquire the virus postnatally (290). 
Postnatal CMV infection in infants born at term, that are protected by maternal derived 
antibodies, usually are asymptomatic and without sequelae. Preterm infants on the other 
hand, having an immature immune system and lacking these protective antibodies are more 
prone to develop a symptomatic infection (291). 
In 2001, Hamprecht et al. reported a transmission rate of 37% of CMV through fresh breast 
milk in very preterm low birth weight infants at their neonatal unit in Tübingen, Germany 
(116). Half of the infected infants developed clinical symptoms or laboratory abnormalities. 
The clinical symptoms included sepsis like symptoms with apnea and bradycardia, 
distended bowel, hepatosplenomegaly and myoclonia while laboratory abnormalities 
comprised neutropenia, thrombocytopenia, raised liver enzymes and elevated C-reactive 
protein (292). Since then many neonatal studies from around the world have been published 
addressing this subject. According to a recent review by Kurath et al., reported transmission 
rates in preterm infants have varied between 6-59% with symptomatic disease in 0-35% of 
infected infants (293). Apart from the clinical picture described above, pneumonitis, 
cholestasis, enterocolitis,  bowel perforation and bowel stricture have been reported while 
more uncommon manifestations are hemophagocytic lymphohistiocytosis and lung cysts 
(294–300) . Risk predictors of severe symptomatic postnatal infection are extreme 
prematurity (<26 weeks), early postnatal infection and high pre-infection comorbidity 
(301). Illustrative of these risk factors,in a retrospective study including only preterm 
infants with a gestational ages 22-24 weeks, 65% of infants born to CMV-seropositive 
mothers presented with a symptomatic infection of which 55% developed sepsis like 
disease (114). 
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Data on the long-term outcome in preterm infants after postnatal CMV infection are 
limited, especially in adolescents; some studies have implied an increased risk for BPD 
(302,303) and a poorer neurodevelopment outcome (304–307), whereas other studies do not 
confirm these findings  (296,308–312).   
To date, we don’t fully know the clinical burden of breast milk acquired CMV infection. 
Consequently, we don’t know if treatment of maternal milk is needed to protect the preterm 
infant from postnatal CMV infection. Furthermore, if preventive measures are needed, the 
risk- benefit ratio of these interventions needs to be better evaluated (313). 
2.3.5 Diagnosis 
Commonly used diagnostic tests for CMV include serology, antigenemia assay, quantitative 
nucleic acid testing, culture and histopathology. 
2.3.5.1 CMV serology 
CMV serology detects CMV specific antibodies and is useful to test whether a patient has 
been previously exposed to CMV, or, if a seroconversion from negative to positive occurs for 
a recent CMV infection. The specificity of IgM antibodies against CMV to prove a primary 
infection is inferior as a false–positive test can occur; likewise patients with reinfection or 
reactivation of a past infection can have IgM antibody to CMV. A primary CMV infection 
can also be confirmed by demonstrating a low CMV-IgG avidity that improves over time 
(264).   
2.3.5.2 Antigenemia assay 
Antigenemia assay is a quantitative method for detection of CMV that uses monoclonal 
antibody to detect the tegument protein pp65 in blood leukocytes by immunostaining. 
According to the clinical setting, the number of pp65-positive leukocytes correlates with risk 
of disease. The assay is easy to perform and does not require expensive equipment but is 
operator dependent and needs to be performed within hours of sample collection (264) . 
2.3.5.3 Quantitative nucleic acid testing 
Quantitative nucleic acid detection is progressively replacing antigenemia assay as a method 
of monitoring CMV load, especially in Europe and North America (314). These techniques 
are highly sensitive and provide viral load measurements that give important prognostic 
information (315). The real time PCR assay, in particular,  is a simple reproducible technique 
able to measure DNA-load in several kinds of specimens (314). However, results can vary 
widely across different testing centers due to the variation in nucleic acid extraction and assay 
design (316).   
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2.3.5.4 CMV culture 
CMV culture is performed by co-culturing clinical specimens with fibroblasts subsequently 
identifying the characteristic cytopathic effect of the virus. Although  slow, expensive and 
labor intensive, CMV culture remains a diagnostic option in tissue invasive CMV disease 
where antigenemia or polymerase chain reaction (PCR) testing on blood may not always be 
positive (316). 
2.3.5.5 Immunohistochemistry (IHC) 
In immunohistochemistry, antibodies are used to detect CMV specific antigens in cells of 
tissue specimens (317) or blood samples.  Immunohistochemistry for CMV can be used on 
biopsy specimens to maximize diagnostic sensitivity where CMV disease is suspected. 
Identification of inclusion bodies or viral antigens in the cells of the biopsy material or 
specimens is characteristic for CMV disease, especially combined with a positive culture 
(316). 
2.3.5.6 In situ hybridization (ISH) 
In situ hybridization is a technique used to localize specific nucleic acid sequences within 
cells in tissue sections or whole cell preparations (318). DNA and RNA sequences are 
visualized by hybridization with labelled complementary strands of nucleic acid. An 
advantage of the methodology is that it allows localisation and visualisation of target 
nucleic acid sequences within morphologically identifiable cells or cellular structures (319). 
2.3.6 Treatment 
To date, the main antiviral agents used to treat CMV infections comprise ganciclovir, 
valganciclovir, cidofovir and forscarnet. Of these, ganciclovir and valganciclovir are the 
gold standard drugs for prophylaxis and treatment of CMV. Second line theraphy options 
against CMV include foscarnet or cidofovir, or the off-label compound leflunomide. High-
dose valacyclovir, penciclovir, famciclovir, and acyclovir have been used for CMV 
prophylaxis in organ transplant recipients. Efficacy is different depending on the transplant 
population, but currently valganciclovir is the most effective drug in use for both 
prophylaxis and treatment of CMV infections. The patent for this compound is expiring in 
August 2015 and several new anti-CMV drugs are in phase II/III trials to be evaluated for 
CMV prophylaxis and treatment; brincidofovir, maribavir and letermovir. Of these 
brincidofovir has a broad antiviral activity and great hope is set to its ability to control 
multiple infections in immunocompromised patients within the next few years. Below is a 
brief description of the currently used drugs for CMV infections. 
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2.3.6.1 Ganciclovir 
Ganciclovir was the first antiviral agent licensed for treating CMV infection. It blocks viral 
DNA synthesis by inhibiting the CMV- DNA- polymerase in CMV infected cells. 
Ganciclovir requires phosphorylation by the viral protein UL 97 to convert to its active 
form. Ganciclovir can only be administrated intravenously. It´s major adverse effects 
include neutropenia, thrombocytopenia and kidney and liver toxicity (320,321). 
Ganciclovir prophylaxis is recommended for CMV- seropositive HIV infected patients with 
low CD4+ T lymphocyte counts (< 50 cells) and in HIV and AIDS patients with previous 
CMV end- organ disease. It is used as antiviral therapy against CMV end-organ disease in 
adults and adolescents with AIDS. Ganciclovir is also used for prevention and treatment of 
CMV disease in transplant patients (322). 
Ganciclovir treatment is recommended in neonates with severe symptomatic congenital 
CMV infection involving the central nervous system as it can improve hearing outcome and 
possibly neurodevelopmental outcome (323). No controlled study has evaluated the impact 
of ganciclovir on the outcome of postnatal CMV infection; however, individual reports 
have described a positive effect of ganciclovir treatment for severe postnatal CMV disease 
in preterm infants  (294,295,324).  
2.3.6.2 Valganciclovir 
Valganciclovir is the ester prodrug of ganciclovir and has the same mechanism of action. It 
is only available in enteral form and is very well absorbed. In adults common side effects 
include diarrhea, nausea, neutropenia, and anemia (325). In neonates neutropenia is a 
reported adverse effect (326).  
Valganciclovir is used as treatment for end-organ disease in AIDS patient, as an alternative 
to ganciclovir in prophylaxis in HIV or AIDS patients with previous CMV end-organ 
disease, for prevention of CMV disease in solid organ transplant patients and for treatment 
of CMV disease in adult and adolescent transplant populations (322).  It is also recently 
accepted as an treatment option against symptomatic CMV infection in neonates (326). 
2.3.6.3 Cidofovir  
Cidofovir is a nucleotide analog that requires phosphorylation by cellular kinases (327). It 
is incorporated into the viral DNA in its active form where it inhibits DNA synthesis (320). 
Cidofovir is administrated intravenously. Nephrotoxicity is the main adverse effect. 
Cidofovir is used as a second-line therapy for treatment of CMV end-organ disease and 
prevention of recurrent CMV end-organ disease in adults and adolescents with HIV or 
AIDS (322). 
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2.3.6.1 Ganciclovir 
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2.3.6.4 Forscarnet 
Foscarnet is an inorganic pyrophosphate analogue administrated intravenously that inhibits 
DNA polymerase by blocking the pyrophosphate binding site. The most common side effects 
are nephrotoxicity and metabolic derangements (328).  
Foscarnet is an alternative therapy in adults and adolescents with AIDS and end- organ 
disease and to prevent recurrence of CMV end-organ disease. It is also used as prophylaxis in 
recipients of allogeneic hematopoietic cells and in CMV disease in transplant patients with 
myelosuppression, or whose virus is resistant to ganciclovir or those who cannot tolerate 
ganciclovir (322) .  
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3 AIMS 
When this thesis project was initiated, the benefits of feeding preterm infants with maternal 
milk were fully acknowledged. However, there was a lack in knowledge and consensus 
regarding the routines used for handling breast milk to limit transmission of CMV to preterm 
infants, as well as the risk of acquiring CMV infection via breast milk. 
The specific aims of this thesis were the following: 
I. To document existing routines pertaining to breast milk use for preterm infants in 
Sweden. 
II. To investigate predictors of maternal milk feedings in EPIs during the first 6 weeks of 
life and at discharge from hospital or home care.  
III. To evaluate the rate and clinical expression of postnatal CMV infection in EPIs in a 
pilot study.   
IV. To evaluate the effect of routine freezing of maternal milk on CMV transmission rate 
and CMV associated disease and neonatal morbidity and mortality in EPIs. 
V. To assess whether NEC, SIP and related surgical conditions are associated with CMV 
infection as a potential consequence of exposure of CMV to the bowel in utero, at 
birth or postnatally through breast milk.  
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4 RESULTS AND BRIEF DISCUSSION 
4.1 BREAST MILK HANDLING ROUTINES FOR PRETERM INFANTS IN 
SWEDEN: A NATIONAL CROSS-SECTIONAL STUDY. (PAPER I) 
This national cross-sectional study was performed as a questionnaire survey in 2006 to 
document existing breast milk handling routines in neonatal units in Sweden awaiting the 
implementation of updated national recommendations on human milk use. 
The strength of the study is that it included all neonatal units in Sweden enabling a national 
overview of the use and handling of human milk for preterm infants.  
We confirmed that in all neonatal units, preterm infants <32 weeks were preferably fed donor 
milk as a complement to maternal milk. Human milk banking was established in the care of 
preterm infants with 27 of the 36 neonatal units having access to a milk bank. Since this 
paper was published, still one more Swedish milk bank has been established and to date, after 
France, Sweden has the second most human milk banks among the European countries (329).  
Although well constituted, none of the 27 milk banks completely followed the prevailing 
Swedish national guidelines from 1998 regarding the recruitment of breast milk donors and 
the handling of donor milk (330). In 7% of the milk banks, donors were not given a health 
declaration in the recruitment process. A complete virology screening of breast milk donors 
against HIV I and II, HTLV type I and type II, HBV and HCV was not performed in 48% of 
the milk banks and donors were not screened for active lung tuberculosis in 85% of the milk 
banks. Donor milk was not routinely pasteurized in 19% of the milk banks and bacterial 
culture was not consistently performed in 11% of the participating milk banks. 
While not endemic in Sweden, the risk of transmission of HTLV type I through the breast 
milk of an infected mother is considerable, with increased the risk of adult T-cell 
leukemia/lymphoma in the offspring (108). Heat treatment of milk by Holder pasteurization 
effectively eliminates HTLV (139). Still, in our study, 2 of the milk banks not screening milk 
donors for HTLV type I did not routinely pasteurize donor milk.  
Five of the milk banks did not screen their donors for HBV and HCV. As the effectiveness of 
Holder pasteurization against HBV and HCV in breast milk has hitherto not been proven or 
evaluated, consistent screening of breast milk donors against these viruses is essential to 
avoid their transmission to donor milk recipients (331). Transmission of tuberculosis through 
breast milk has never been documented in the absence of tuberculosis mastitis, which is rare 
(117). In the newly revised national guidelines by Milknet, screening of milk donors with a 
lung X-ray to exclude active tuberculosis is mainly underscored in those milk banks where 
unpasteurized breast milk is used (135)  .  
The Holder pasteurization was the most common mode of heat treatment used on donor milk. 
Although this technique is known to eradicate the most common bacterial contaminants in 
human milk, endospores of the Bacillus species and enterotoxin of Staphylococcus aureus 
can resist the pasteurization process and cause disease in susceptible preterm infants 
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(141,332) . Likewise, if donor milk becomes contaminated by microorganisms after 
pasteurization, their growth will be enhanced as the pasteurization process damages 
antimicrobial components of the milk (139). Therefore, in some countries, postpasteurization 
bacterial culture is considered an important part of the donor milk screening process (135). 
However, at the human milk bank of Rikshospitalet University Hospital in Oslo, Norway, 
donor milk with low bacterial count is used for the most preterm infants, and, remarkably, 
although the donor milk is dispensed unpasteurized the reported incidences of both NEC and 
LOS among preterm infants at that centre are low (333,334). 
In this study, preventive treatment of maternal milk with regard to CMV transmission was 
inconsistent among the neonatal units. In accordance with the recommendations of the 
Swedish National Board of Health and Welfare, 31% of the neonatal units routinely fed their 
preterm infants with freeze-thawed maternal milk in order to reduce the risk for CMV 
transmission. At that time, in vitro studies had shown that the CMV load in breast milk could 
be decreased considerably by freezing the milk 3-4 days (149,335). 
However, the time the mother’s own breast milk was kept frozen before use varied between 
the units from a few hours to 7 days.  
In the remaining 69% of neonatal units in Sweden, and contradictory to prevailing 
recommendations, early feedings with fresh maternal milk were permitted. This may reflect a 
common reluctance to routine freezing of maternal milk as no randomized clinical study had 
yet shown true effect of freezing on postnatal CMV transmission. Likewise, the reputed 
beneficiary anti-inflammatory and trophic effects of early human milk feedings may have 
affected the breast milk handling routines (336).  
In our study, nutritional analysis of donor milk was performed in 63% of the milk banks and 
of maternal milk in 61% of the neonatal units. The composition of human milk is influenced 
by gestational age and is variable within feedings, diurnally, over lactation, and between 
mothers (26,27,29,30). Therefore, and because of the special nutrient requirements in the 
preterm infant, protein and energy fortification of breast milk after nutritional analysis is most 
desirable to improve outcome and to prevent nutritional disorders (337). 
4.2 PREDICTORS OF SUSTAINED MATERNAL MILK FEEDS IN EXTREMELY 
PRETERM INFANTS. (PAPER II) 
In this prospective cohort study, including 97 singleton EPIs and their mothers at the 
Karolinska University Hospital and the Stockholm South General Hospital, predictive factors 
of maternal milk feedings in EPIs during the first 6 weeks of life and at discharge were 
investigated.  
This is the first study in a country with high breastfeeding rates to examine predictors for 
sustained maternal milk provision in EPIs. A weakness in the study was that the cohort 
derived from another randomized study (study IV) where study subjects were initially 
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allocated to separate feeding groups. However, no associations were found between the 
randomization groups and the outcome measures in our study. 
At the end of the sixth week, 80% of mothers were still producing breast milk. In 
comparison, in the study by Stoltz Sjöström et al., using data of EPIs born < 27 weeks 
between 2004-2007 from the Swedish Express study, 71% of infants were at least partly fed 
with maternal milk during postnatal week 4 to 8, indicating that the same proportion of 
mothers of these infants were producing breast milk (28).   
We found that the mean proportion of enteral feedings that were maternal milk feedings 
during the first 6 weeks of life was 69%. The proportion of maternal milk feedings reached a 
maximum during the third week of life (76%) after which expressed volumes of maternal 
milk could not keep up with the infants’ increasing enteral feedings. We believe that the 
observed diminishing milk production may reflect the occurrence of the physiological switch 
from central to autocrine control of milk production, during which lactation becomes more 
dependent on the frequent and total emptying of the breast than on hormonal control (338). 
At discharge, 66% of EPIs were provided with maternal milk; 13% were exclusively 
breastfed, 13% were breastfed and bottle fed with maternal milk only and 39% were fed a 
combined diet of maternal milk and formula. Correspondingly, in the study by Stoltz 
Sjöström et al., 50% of infants were fed maternal milk at discharge; of these 89% were 
exclusively or partly breastfed whereas 11% were bottle fed with maternal milk (28). In a 
previous study on breastfeeding rates at discharge in preterm infants at Danderyds Hospital, 
Stockholm, 76% of EPIs were exclusively or partly breastfed at discharge; in that study, a 
much higher proportion (38%) of the EPIs were exclusively breastfed than in our study (250). 
Since that study was performed, however, the overall rates of exclusive breastfeeding have 
been decreasing in Sweden (15). Other possible reasons that could have contributed to lower 
breastfeeding rates observed in our study may be that the EPIs in our study were more ill 
and/or that mothers of EPIs received less support during the process of transition to 
breastfeeding.   
We found that high maternal milk feedings in EPIs during week 2 were positively associated 
with both the proportion of maternal milk feedings the first 6 weeks of life and with exclusive 
maternal milk feedings at discharge. Additionally, the proportion of maternal milk feedings 
during the first 6 weeks of life was related to the provision of maternal milk feedings at 
discharge. Consistently, Hill et al. demonstrated that milk volumes at week 2 were predictive 
of milk volumes at week 5 in mothers of very preterm VLBW infants and that high milk 
volumes during the first 6 weeks were predictive of sufficient maternal milk at 12 weeks 
postpartum (339,340). Another recently published study from Sweden found a relationship 
between volumes of maternal milk provided at day 3 and 7 and exclusive maternal milk 
feedings at 36 weeks post menstrual age in preterm infants born between 28 and 32 weeks but 
this association was not found in infants < 28 weeks of gestation (341) . 
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Interestingly, assisted reproduction technology was a favorable predictor for both exclusive 
maternal milk feedings and exclusive breastfeeding at discharge. Conversely, 2 other studies 
have reported lower breastfeeding rates among women at 6 weeks and 3 months, 
respectively, after conception with assisted reproductive technology (342,343). However, 
these were mothers of both term and preterm infants. In our study, mothers conceived by 
assisted reproduction technology may have been more motivated to breastfeed than the other 
mothers in the study, accomplishing breastfeeding success through their continuous access to 
counselling and support by neonatal personnel.  
Maternal overweight was an unfavorable predictor of high maternal milk feedings during 
week 2 and of maternal milk feedings at discharge. Maternal overweight is an identified risk 
factor for failure to initiate and sustain breastfeeding (344,345) but to our knowledge,  this 
relationship is not previously identified for mothers of EPIs. Overweight may by biological 
mechanisms reduce the maternal prolactin response to suckling, thereby causing a delay of 
lactogenesis II which render the predisposed preterm mothers at a greater risk for lactation 
failure (346). 
Non-university education and non-Nordic origin were negatively associated to the proportion 
of MMFs the first 6 weeks of life. In a study by Hill et al., income was the only maternal 
demographic factor that was independently predicting milk output at week 6 in mothers of 
very preterm VLBW infants; income in turn was positively related to both maternal education 
and ethnicity (347). On the contrary, in a study investigating milk output in pump-dependent 
mothers of preterm infants < 31 weeks, maternal education was not related to milk volume at 
week 8 postpartum (244).  
In our study, age was the only favorable maternal predictor for the provision of maternal milk 
feedings at discharge. Results of  previous studies investigating the effect on maternal age on 
lactation duration in mothers of very preterm or VLBW infants are contradictory, some report 
an association (348,349) whereas other studies do not confirm any relationship 
(242,350,351).  
4.3 TRANSMISSION OF CYTOMEGALOVIRUS TO EXTREMELY PRETERM 
INFANTS THROUGH BREAST MILK. (PAPER III) 
This pilot study, including 10 EPIs and their 6 mothers, was performed in 2002 to evaluate 
the rate and clinical expression of breast milk induced CMV infection in EPIs at the Neonatal 
Unit, Astrid Lindgrens Children´s Hospital. 
Five out of 6 (83%) mothers were CMV-seropositive. Of these, 4 (80%) excreted CMV-DNA 
and 2 (40%) mothers had a positive CMV culture. By comparison, in the pioneering study of 
Hamprecht et al. on CMV transmission to very preterm infants in 2001, 96% of seropositive 
mothers had detectable CMV- DNA in breast milk and 76% had positive virus isolation in 
breast milk  (116).  
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Transmission of CMV occurred in 2 of 7 (29%) EPIs that were fed both fresh and freeze-
thawed CMV-positive breast milk. At that time, as still today, the reported transmission rates 
of CMV to preterm infants through breast milk varied considerably between prospective 
studies depending on the study design and prevailing feeding protocols and human milk 
treatment at the study centers.  
Thus, at that time, Vochem et al. from Germany reported a transmission rate of 59% to very 
preterm infants fed only fresh maternal milk with formula as supplemental feedings whereas 
Mussi Pinhata et al. from Brazil reported a transmission rate of 22% in infants < 34 weeks fed 
fresh maternal milk supplemented with donor milk (113,352). By comparison, Jim et al. from 
Taiwan reported a transmission rate of 15% in infants < 33 weeks that were only fed freeze-
thawed milk supplemented with formula (311).  
Contrariwise, Yasuda et al. from Japan and Doctor et al. from Canada only reported a 
transmission rate of 10% and 6% in infants < 34 weeks and < 1000 gram, respectively, that 
were fed predominantly freeze-thawed maternal milk with formula as supplement (353,354).   
In this pilot study, only infants that were fed with breast milk with a positive viral culture 
were infected by CMV. Early excretion of CMV-DNA in breast milk and virolactia, the 
presence of  infectious virus in breast milk, are both associated to increased risk of CMV 
transmission to the preterm infant (116,311). Also, some studies have found a higher load of 
CMV-DNA in breast milk of CMV transmitting mothers (355,356). In both the CMV 
infected infants, CMV-DNA was detected in breast milk sampled during the first 2 weeks 
postpartum. However, in the samples of milk fed to one of these infected infants, the amount 
of CMV- DNA was so low that it could not be detected with quantitative analysis. A 
discrepancy between CMV-DNA load and viral infectivity has been observed in other studies 
(353,357) and could be explained by the fact that some of the viral particles detected by DNA 
analysis are incomplete and thus replicate-incompetent virions (149).  
None of the infected infants presented with overt clinical symptoms at the time of the CMV 
infection. However, one of the infected infant developed liver involvement with laboratory 
abnormalities. Early postnatal CMV transmission and low birth weight are both reported risk 
factors in premature infants for developing symptomatic postnatal CMV disease (292,358). 
Likewise, postnatal CMV infection may aggravate the course of a pre-existing hepatic 
condition in preterm infants (296). Indeed, the CMV infected infant with liver involvement 
was the most preterm of all EPIs, he had an earlier postnatal excretion of CMV in the urine 
compared to the other infected infant, and he had at that time an unrecognized cystic fibrosis 
that was later diagnosed.  
4.4 CYTOMEGALOVIRUS INFECTION AND NEONATAL OUTCOME IN 
EXTREMELY PRETERM INFANTS AFTER FREEZING OF MATERNAL 
MILK. (PAPER IV) 
This clinical trial, conducted from 2005 to 2009 at the Karolinska University Hospital and the 
Stockholm South General Hospital, evaluated the effect of routine freezing of maternal milk 
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presence of  infectious virus in breast milk, are both associated to increased risk of CMV 
transmission to the preterm infant (116,311). Also, some studies have found a higher load of 
CMV-DNA in breast milk of CMV transmitting mothers (355,356). In both the CMV 
infected infants, CMV-DNA was detected in breast milk sampled during the first 2 weeks 
postpartum. However, in the samples of milk fed to one of these infected infants, the amount 
of CMV- DNA was so low that it could not be detected with quantitative analysis. A 
discrepancy between CMV-DNA load and viral infectivity has been observed in other studies 
(353,357) and could be explained by the fact that some of the viral particles detected by DNA 
analysis are incomplete and thus replicate-incompetent virions (149).  
None of the infected infants presented with overt clinical symptoms at the time of the CMV 
infection. However, one of the infected infant developed liver involvement with laboratory 
abnormalities. Early postnatal CMV transmission and low birth weight are both reported risk 
factors in premature infants for developing symptomatic postnatal CMV disease (292,358). 
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that was later diagnosed.  
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on CMV transmission, symptomatic CMV infection and mortality and morbidity during 
neonatal stay in EPIs. One hundred and forty EPIs were randomized to be fed only with 
freeze-thawed maternal milk (intervention group) or with fresh and freeze-thawed milk 
according to existing clinical practice (control group).   
This randomized trial is the first of its kind to evaluate the effect of routine maternal milk 
freezing on breast milk acquired CMV infection and neonatal outcomes in EPIs.  
The strength of the study was the detailed documentation of the enteral feedings in all EPIs 
during their first 6 weeks of life demonstrating a well-functioning intervention procedure. 
By baseline characteristics comparison we found that significantly more infants in the control 
group were born SGA and delivered by caesarean section. Likewise, pre-eclampsia was more 
common in mothers in the control group. Pre-eclampsia is a known risk factor for intrauterine 
growth retardation and SGA (359). For elective delivery of an intrauterine growth retarded 
foetus during the very preterm period, caesarean section is the method of choice (360). 
Indeed, in our study, 60% of mothers with pre-eclampsia delivered infants that were SGA 
compared to 11% of mothers without pre-eclampsia. Similarly, 96% of all infants with SGA 
were delivered with caesarean section.  
In this clinical trial, the overall CMV transmission rate to infants fed CMV-positive breast 
milk was much lower than in the previous pilot study performed in our unit (7% vs. 29%). No 
significant difference in CMV transmission rates was found between the study groups. The 
predefined sample size for our study was based on the documented CMV transmission rate of 
the pilot study, that was similar to reported rates of postnatal CMV transmission at other 
neonatal centres using fresh maternal milk at that time  (352,361) . As the CMV transmission 
rate proved to be lower than expected, the sample size estimation was insufficient to detect 
significant differences in CMV transmission rates and symptomatic CMV infection between 
the study groups.  
The transmission rates in CMV exposed EPIs fed only freeze-thawed maternal milk or fresh 
and freeze-thawed maternal milk were similar; 8% and 6%, respectively. None of the infected 
EPIs developed clinical symptoms at the time of CMV transmission but one infected infant in 
each group developed transitory cholestasis. The highest rate of breast milk acquired CMV 
transmission with clinical CMV disease in very preterm/VLBW infants hitherto reported in a 
prospective study is by the research group from Tubingen, Germany (113). In their first 
report, 17/29 (59%) of very preterm infants fed milk from CMV-seropositive mothers 
excreting CMV in milk became infected by the virus; 10 of the infected infants developed 
clinical or laboratory abnormalities. Infants were only fed fresh maternal milk with formula 
feedings as supplement if needed. Another recent retrospective study including only infants 
with gestational ages 22-24 weeks reported symptomatic CMV infection in 11/17 (65%) of 
infants fed fresh untreated maternal milk from CMV seropositive mothers. In that study, the 
type of supplemental feeds used were not stated (114). 
 
 55 
on CMV transmission, symptomatic CMV infection and mortality and morbidity during 
neonatal stay in EPIs. One hundred and forty EPIs were randomized to be fed only with 
freeze-thawed maternal milk (intervention group) or with fresh and freeze-thawed milk 
according to existing clinical practice (control group).   
This randomized trial is the first of its kind to evaluate the effect of routine maternal milk 
freezing on breast milk acquired CMV infection and neonatal outcomes in EPIs.  
The strength of the study was the detailed documentation of the enteral feedings in all EPIs 
during their first 6 weeks of life demonstrating a well-functioning intervention procedure. 
By baseline characteristics comparison we found that significantly more infants in the control 
group were born SGA and delivered by caesarean section. Likewise, pre-eclampsia was more 
common in mothers in the control group. Pre-eclampsia is a known risk factor for intrauterine 
growth retardation and SGA (359). For elective delivery of an intrauterine growth retarded 
foetus during the very preterm period, caesarean section is the method of choice (360). 
Indeed, in our study, 60% of mothers with pre-eclampsia delivered infants that were SGA 
compared to 11% of mothers without pre-eclampsia. Similarly, 96% of all infants with SGA 
were delivered with caesarean section.  
In this clinical trial, the overall CMV transmission rate to infants fed CMV-positive breast 
milk was much lower than in the previous pilot study performed in our unit (7% vs. 29%). No 
significant difference in CMV transmission rates was found between the study groups. The 
predefined sample size for our study was based on the documented CMV transmission rate of 
the pilot study, that was similar to reported rates of postnatal CMV transmission at other 
neonatal centres using fresh maternal milk at that time  (352,361) . As the CMV transmission 
rate proved to be lower than expected, the sample size estimation was insufficient to detect 
significant differences in CMV transmission rates and symptomatic CMV infection between 
the study groups.  
The transmission rates in CMV exposed EPIs fed only freeze-thawed maternal milk or fresh 
and freeze-thawed maternal milk were similar; 8% and 6%, respectively. None of the infected 
EPIs developed clinical symptoms at the time of CMV transmission but one infected infant in 
each group developed transitory cholestasis. The highest rate of breast milk acquired CMV 
transmission with clinical CMV disease in very preterm/VLBW infants hitherto reported in a 
prospective study is by the research group from Tubingen, Germany (113). In their first 
report, 17/29 (59%) of very preterm infants fed milk from CMV-seropositive mothers 
excreting CMV in milk became infected by the virus; 10 of the infected infants developed 
clinical or laboratory abnormalities. Infants were only fed fresh maternal milk with formula 
feedings as supplement if needed. Another recent retrospective study including only infants 
with gestational ages 22-24 weeks reported symptomatic CMV infection in 11/17 (65%) of 
infants fed fresh untreated maternal milk from CMV seropositive mothers. In that study, the 
type of supplemental feeds used were not stated (114). 
 56 
In our study, 2/3 of the enteral intake the first 6 weeks in both groups was maternal milk; in 
controls, 37% of maternal milk was fresh milk. Until week 34 of gestation, insufficient 
maternal milk feedings in infants were supplemented with donor milk, not with formula. 
Early feedings with formula may have unfavourable effects on the immunological protective 
mechanisms of the immature gut, affecting mucosal structure and function and the intestinal 
microbial environment (362). Therefore, EPIs fed untreated fresh maternal milk containing 
CMV in a combination with formula may become more susceptible to CMV infection. 
Contrariwise, human milk contains a large number bioactive factors and a variety of microbes 
that together are thought to interact to protect and promote the development of the mucosal 
immune system (2,202). Thus, the relatively low amount of fresh MM and the use of 
pasteurized donor milk instead of formula may thus have contributed to the low transmission 
rate and lack of symptomatic infection among infected infants in our study. 
In our study, the rate of neonatal death was similar in the study groups; 6% in both groups by 
intention to treat analysis and 7% in the intervention group and 6% in the control group by 
per protocol (PP) analysis. All deaths occurred after the first week of postnatal life. Late onset 
septicaemia, a recognized contributor to mortality in infants born very preterm, was the most 
common cause of death, occurring in 5 of the 8 (63%) deceased infants. Similarly, 
septicaemia was the most frequent diagnosis among infants in the Swedish Express study in 
infants who died after the first week (164). 
Using PP analysis, including infants who remained in the study throughout their neonatal 
stay, the overall incidence of late onset septicaemia was 51% (62/121); bacterial sepsis was 
observed in 45% (54/121) of infants and fungal sepsis in 7% (8/121) of infants. 
Correspondingly, in the Swedish express study the overall rate of culture proven septicaemia 
in infants surviving the first year of life was 41% and most of these were acquired 
nosocomially (164). In our study, fungal LOS only occurred in the control group with an 
observed frequency of 12% analysis compared to 0% in the intervention group using both 
analyses. All infections were caused by the Candida species and all occurred in the first half 
of the study period before fungal prophylaxis had been fully introduced in our neonatal units. 
A primary risk factor for neonatal Candidiasis is colonization of skin and mucosa with 
Candida (363). In our study, a potential source leading to Candida colonization may have 
been expressed breast milk contaminated by Candida from mother’s skin or from milk 
containers during the milk pumping process (364). As freezing of maternal milk deactivates 
yeast, while still preserving some important immunological components of the milk, the 
provision of freeze-thawed maternal milk could have some preventative advantages over 
fresh maternal milk feedings with respect to fungal infections during neonatal stay when 
fungal prophylaxis is not practised (149,365). 
Other known risk factors for invasive Candida infections are prematurity, low birth weight, 
intubation, the use of central catheters, prolonged treatment with broad spectrum antibiotics 
and parenteral nutrition (363). Indeed, we found that the EPIs with Candida LOS were treated 
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significantly longer on ventilator and had longer treatments with antibiotics and parenteral 
nutrition compared to infants without Candida LOS. 
According to PP analysis, the proportion of infants in our study with BPD, NEC and ROP in 
the study was 46%, 8% and 31%. Corresponding numbers among surviving infants in the 
Swedish express study were 73%, 6% and 34% (164). The occurrence of BPD, NEC and 
ROP tended to be higher among infants in the control group that were partly fed with fresh 
maternal milk although this did not reach statistical significance.    
In this trial, 3 EPIs were diagnosed with congenital CMV infection by postnatal urine 
screening. As all infants were asymptomatic, the infection was only detected due to the 
CMV screening in the randomized study, and not by clinical testing upon indication. The 
proportion of congenital CMV infection among all EPIs initially screened in urine in our 
study was 2% and thus considerably higher than the previous reported frequency of 
congenital CMV infection of 0.5% among newborns in Malmö in 1977 to 1986  and of 
0.2% among newborns in Stockholm in 2003 to 2004 (266,366). To our knowledge, no 
study has hitherto evaluated the prevalence of congenital CMV infection in a population of 
EPIs. It is possible that a variable activity of CMV in the society over several years may 
have affected the different results (367) or that our findings may be a matter of chance due 
to the small number of study subjects screened. However, congenital CMV infection is 
associated to both prematurity and low birth weight (368,369) and considering the 
increased risk of neurological sequelae after both congenital infection and among EPIs, 
more studies are needed to appraise the potential value of routine surveillance for 
congenital CMV in EPIs. 
4.5 HIGH PREVALENCE OF CYTOMEGALOVIRUS INFECTION IN SURGICAL 
INTESTINAL SPECIMENS FROM INFANTS WITH NECROTIZING 
ENTEROCOLITIS AND SPONTANEOUS INTESTINAL PERFORATION; A 
RETROSPECTIVE OBSERVATIONAL STUDY. (PAPER V) 
In this retrospective observational study, 70 intestinal samples from 61 infants that underwent 
surgery for NEC, SIP or related surgical conditions at the Karolinska University Hospital 
Solna and the Uppsala University Hospital were investigated for the presence of CMV 
infection. Ten intestinal specimens from autopsied infants without bowel disease were used 
as controls.  
NEC is a feared disease in preterm infants due to its high mortality rates, surgical 
complications and increased risk of the comorbidities of prematurity (192). SIP, although not 
presenting as deleterious as NEC, is also associated to increased risk of death and long-term 
morbidity in the most preterm infants (370).  
Up until now, no study has investigated the prevalence of CMV infection in a larger cohort of 
infants with these surgical disorders; still, several case reports and case series have been 
published where histopathologic findings compatible with CMV infection have been detected 
in the bowel of infants with NEC, intestinal perforation or intestinal stricture (300,324,371–
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373). 
By using an IHC technique with antibodies directed against two different CMV proteins, 
CMV-immediate early antigen (CMV-IEA) and CMV-late antigen (CMV-LA), we could 
detect CMV-IEA in 81% (57/70) and CMV-LA in 64% (45/70) of tissue samples. In contrast, 
only 2/10 (20%) control specimens were positive for CMV-IEA and CMV-LA by IHC. 
In index specimens, the prevalence of CMV antigens was highest in specimens with the 
pathologic diagnosis NEC with intestinal perforation; 95% were positive for CMV-IEA and 
79% were positive for CMV-LA. Still, CMV antigens were found in more than half of the 
specimens with the pathologic diagnoses NEC, SIP and post inflammatory changes after 
NEC or SIP. Thus, CMV proteins were prevalent in the intestinal specimens irrespective of 
pathologic diagnosis. 
In order to further confirm the presence of CMV in the collected bowel samples, we 
performed complementary tests for detection of CMV nucleic acids in selected intestinal 
tissue specimens.  
In 10 intestinal specimens positive for CMV-IEA by IHC, CMV-positive cells were collected 
by laser capture microdissection with subsequent analysis of CMV-DNA by Taqman PCR. 
CMV-DNA was detected in 4/10 (40%) specimens. A discrepancy in the number of cells 
positive for CMV-antigens and CMV-DNA have previously been described by our group in 
tissue specimens from glioblastoma patients (374) and may illustrate the presence of non-
replicating viral protein expressing cells. These cells may contain viral nuclei acids delivered 
via defective virus particles such as dense bodies or exosomes to intestinal epithelial cells 
(375,376). 
Likewise, CMV-DNA was detected by in situ hybridization in 13/13 (100%) intestinal tissue 
sections from infants with positive IHC- CMV-IEA staining; however 3/ 5 (60%) tissue 
sections from infants with IHC- CMV-IEA negative staining were also positive for CMV-
DNA by ISH. These findings could reflect a latent CMV infection in the bowel of these 
infants, or this might be a result of non-serial sections of the intestinal specimens used for the 
different analyses. 
In our study, all NEC samples were retrieved from infants who had undergone surgery due to 
advanced NEC, SIP or related surgical complications. CMV infection was prevalent 
regardless of diagnosis, also in SIP patients presenting earlier in life. We speculate that the 
high prevalence of CMV in the intestine of index cases may be explained by a frequent, but 
hitherto underestimated prenatal, perinatal or postnatal exposure to CMV through blood, 
amniotic fluid, genital secretions or breast milk. 
In NEC, it is possible that CMV nucleic acids and proteins are delivered to the bowel mucosa 
by exosomes or defective CMV particles present in amniotic fluid or breast milk leading to 
viral protein expression, presentation of viral peptides to the immune system and an 
aggravated inflammation. The local non-permissive CMV infection resulting in expression of 
viral proteins or the sole presence of CMV antigens may cause a disturbance in cell functions 
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(279) and a disruption in the epithelial barrier (377) and mediate an inflammation by 
stimulating an immune response directed against CMV peptides; this may aggravate the 
underlying pathology of NEC and contribute to disease progression. Inflammation by itself 
would also provide a microenvironment conducive for reactivation of latent CMV 
aggravating a pre-existing inflammation (378).  
Whereas hemorrhagic-ischemic necrosis, inflammation and bacterial overgrowth are 
distinguishing pathologic features of NEC, the histopathology of the bowel in SIP reveals 
focal perforation, usually in the ileum, sometimes associated with necrosis in the muscularis 
externa (379).  So, is it possible that CMV through other ways can contribute to the 
pathogenesis of SIP? The virus is able to infect both epithelial cells and smooth muscle cells 
that could result in a lytic infection with necrosis and bowel perforation. Also, through down 
regulation of the essential gap junction component connexin 43, loss of gap junction function 
could mediate loss of barrier integrity leading to SIP (377).  
The most common route of postnatal CMV transmission to the preterm infant is maternal 
milk. However, human milk intake is the single most important preventive measure against 
NEC in preterm infants. The exact protective components by which human milk exerts its 
effect are not fully known; however, human milk shapes the development of the intestinal 
microbiota that is thought to play an essential role in the development of NEC (202). In 
addition, human milk contains immune-related, anti-infective and immune-modulatory 
components conferring additive innate immunity to the gastrointestinal tract (49,380). 
We arbitrarily collected 10 specimens from autopsied infants without bowel disease as 
controls in our study. Although these infants were all born preterm, their median gestational 
age and median birth weight did not differ significantly from that of the index infants.  
Unfortunately, the postnatal age of the control index infants at intestinal sampling was 
significantly lower than in index infants (3 days vs 20 days) making it an unrepresentative 
control sample for the study. However, despite these dissimilarities, we only detected CMV 
infection in 20% of the control samples compared to in 81% in samples from index infants. 
Thus, we reason that the post mortem samples also provide an important control for the IHC 
assays used to detect CMV proteins. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
It is becoming increasingly evident that human milk is the most optimal nutrition for the 
preterm infant and so far very preterm infants in Sweden are preferably fed human milk, 
either expressed mother’s own milk or donor milk.  
The goal of our work herein was to document how human milk is handled before its use for 
preterm infants in Sweden. We also wanted to investigate what maternal factors were 
predictive for lactation success or lactation insufficiency in mothers of EPIs. Likewise, we 
wanted to evaluate the effect of routine freezing of maternal milk on the rate of postnatal 
CMV infection and the morbidity and mortality outcomes in EPIs. Finally, we wanted to 
investigate the occurrence of CMV infection in intestinal specimens from infants with NEC, 
SIP and surgical conditions related to these diseases.  
In paper I, we could confirm an established role of human milk banking in the care of preterm 
infants. However, none of the neonatal unit entirely followed the prevailing recommendations 
by the Swedish National Board of Health and Welfare and we could observe that donor 
screening and analysis and treatment of human milk varied among the neonatal units. In 
parallel with this survey, ambitious work was performed by a group of representatives from 
the Swedish Milknet network, revising issues concerning the treatment and use of human 
milk, which resulted in updated national recommendations on breast milk handling and breast 
milk use in 2008. These recommendations were later revised in 2011 and are currently under 
the process of a new revision. In addition, the Milknet network has held regular national 
meetings both for education and for exchange of knowledge in matters pertaining to breast 
milk use that have been well incorporated by neonatal personnel. It is our believe that today, 
owing to these cooperative national measures, practices pertaining to breast milk handling in 
the neonatal care in Sweden are improved and more uniform. However, a new national 
survey will be needed to confirm this.  
In paper II, we found that the establishment of high maternal milk feedings in EPIs at second 
week was important for sustained maternal milk intake the first 6 weeks of life, which in turn 
was positively associated with the provision of exclusive maternal milk feedings at discharge. 
Thus, according to the results of our study, mothers of EPIs should try to establish high breast 
milk volumes shortly after delivery in order to promote lactation success.  
Likewise, in our study, non-Nordic origin and non-university education were unfavorable 
predictors of maternal milk intake the first 6 weeks of life whereas young maternal age and 
overweight were unfavorable predictors of any maternal milk feedings at discharge. 
Accordingly, mothers of EPIs without university education or of non-Nordic origin, young 
mothers and overweight mothers may be mothers in need of special interventions to avoid 
lactation insufficiency.   
Through this new knowledge, and the documentation that breastfeeding rates have decreased 
recently, it has become evident that interventions are necessary to improve overall breastmilk 
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provision by mothers of preterm infants. At the Karolinska University Hospital, the 
collaborative work to educate and instruct engaged neonatal and obstetrical personnel in 
supporting mothers of EPIs in order to optimize breast milk production has been improved. 
Likewise, at the Stockholm South General Hospital, a “Breastfeeding group” of personnel 
from the neonatal unit has been formed that is responsible to educate, support and guide 
parents and care givers of admitted infants in issues of lactation and breastfeeding.   
In the pilot study of paper III, we observed a rather high postnatal CMV transmission rate 
(29%) in EPIs fed with fresh and freeze-thawed CMV-positive maternal milk in our unit, 
with an aggravated course of a pre-existing liver condition in one of the two infected infants. 
Consequently, we became concerned about the potential risks of feeding our most preterm 
infants with untreated maternal milk with CMV transmission in mind.  
Pasteurization was not considered a treatment of choice because of the detrimental effect of 
the heating procedures on many important milk components. At that time, the Swedish 
National Board of Health and Welfare recommended freezing of milk of CMV-seropositive 
mothers to infants < 32 weeks but no clinical trial had been performed to prove the effect of 
freezing on CMV transmission or CMV disease in EPIs. Likewise, as studies had shown that 
early feedings with fresh maternal milk was beneficiary for the preterm gut and immunity, we 
were apprehensive about the possible effects of routine freezing of maternal milk on neonatal 
outcome.   
For this dilemma, we performed the randomized study of paper IV, aiming to evaluate the 
effect of routine freezing of maternal milk on postnatal CMV infection and neonatal outcome 
in EPIs. In this much larger study however, including 140 EPIs randomized to be fed either 
only freeze thawed maternal milk (intervention group) or both fresh and freeze-thawed 
maternal milk (control group), the overall postnatal CMV transmission to infants fed CMV- 
positive breast milk turned out to be much lower than in the pilot study, or 7%. With this 
unexpected lower transmission rate than in the pilot study, and loss of the original projected 
power, we could not demonstrate that routine freezing affected the rate of CMV transmission. 
The postnatal CMV transmission rate was 8% in the intervention group and 6% in the control 
group. Of only five infected infants, none presented with clinical symptoms but one infant in 
each group had transitory cholestasis. Thus, breast milk acquired CMV transmission rate was 
low, not affected by routine freezing and CMV infection did not cause overt symptomatic 
disease in the infected infants.  
In contrast, by our CMV screening, we found a prevalence of congenital CMV infection of 2 
% in the EPIs, a rate ten times higher than that in a previous population based Swedish report. 
To date, routine screening of congenital CMV infection is not performed among newborn 
infants in Sweden. Still, considering that extreme prematurity and congenital CMV infection 
both can affect neurodevelopmental outcome, we believe that EPIs might be a target group 
for routine surveillance in the future, especially if other studies also confirm a higher 
prevalence of congenital CMV infection among EPIs.  
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In our clinical trial, routine freezing of all maternal milk did not affect mortality during 
neonatal stay. With respect to morbidity, infants in the group that were partly fed with fresh 
maternal milk tended to have more BPD, NEC, ROP and bacterial sepsis, but this was not 
statistically significant. Surprisingly, LOS by candida was only observed in infants that were 
partly fed with fresh maternal milk and became less frequent after fungal prophylaxis was 
implemented in our units. One possible explanation of this finding is that expressed maternal 
milk may have been contaminated by Candida but that the freezing procedure prevented 
against subsequent invasive infection by deactivation of the yeast. Therefore, fresh maternal 
milk might have constituted an increased risk for fungal sepsis in EPIs that was countered by 
prophylaxis administration.  
With the demonstrated low transmission rate of postnatal CMV infection and the subtle 
clinical manifestations observed in the infected infants in our study, EPIs in our neonatal 
units in Stockholm are still fed with fresh maternal milk in a combination with freeze-thawed 
maternal milk. Since this clinical trial was completed, there has been to our knowledge two 
observed cases of severe postnatal CMV infection in Stockholm. With respect to the possible 
potential benefits of routine freezing of maternal milk on morbidity in EPIs, further studies 
are needed to confirm these findings before the implementation of routine maternal milk 
freezing can be considered in our unit. Likewise, although fungal infections seem to be less 
prevalent in EPIs in our units after the introduction of prophylaxis, there is a need to perform 
a review to revise these numbers. Last but not least, the potential long-term effects in our 
CMV infected infants has yet not been evaluated and may come to guide us further in the 
future on if or how to treat maternal milk in EPIs.  
In paper V, we hypothesized that CMV through transfer to the intestinal mucosa could 
contribute to disease pathogenesis in NEC, SIP and related surgical conditions. For this 
purpose, we collected 70 intestinal specimens from 61 infants that underwent surgery for 
these causes; 10 intestinal specimens from autopsied infants without bowel disease were used 
as controls. Strikingly, and to our surprise, we could detect the presence of specific CMV 
proteins by IHC staining in a majority of these specimens; 81% were positive for CMV-IEA 
and 64% were positive for CMV-LA. The occurrences were highest in infants with the most 
advanced NEC with bowel perforation where 95% of specimens were positive for IEA and 
89% positive for LA. On the other hand, CMV antigens were only detected in 20% of the 
control samples. Furthermore, by CMV-DNA analysis with ISH and Taqman PCR after laser 
capture microdissection in selected intestinal specimens, we could further confirm the 
occurrence of CMV infection in several infants. 
We reason that maternal CMV transmission either could occur to the fetal gut in utero or to 
the infant gut at delivery or postnatally through breast milk. In the preterm infant the gut is 
functionally immature and in a susceptible immunologic state due to an immature adaptive 
immune system making it more vulnerable to the exposure of microorganisms and foreign 
proteins. CMV is an opportunistic virus, known to cause colitis in the immunocompromised 
adult patient and is also proposed to act as a co-pathogen in adults with inflammatory bowel 
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disease. By interacting with the dysfunctional immune system in these infants, it could 
readily take advantage of the exposed immature gut of the preterm infant, inducing or 
aggravating a pre-existing inflammation in the mucosa, affecting mucosal permeability or 
even by lytic infection induce a local bowel perforation.  
To conclude, our findings may indicate a possible role of CMV in the pathogenesis of severe 
NEC, SIP and related surgical conditions, aggravating the course of these diseases, leading to 
surgery. Progress in the treatment and prevention of NEC in the past decades has been almost 
none, and we hope our results might open up for new therapeutic possibilities for affected 
infants in the future. We suggest that routine screening for CMV should be undertaken in 
infants with these surgical manifestations, however, as these infants may not be viremic or 
have viruria due to a compartmentalised CMV infection in the bowel, new screening methods 
or potential biomarker need to be developed. Future studies should thus aim to explore 
reliable screening methods to confirm the high prevalence of CMV in NEC/SIP found in our 
study, to understand the pathogenic relevance of CMV in these diseases and to evaluate 
whether CMV targeted therapies may be of benefit for some of these patients.   
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6  SVENSK SAMMANFATTNING 
Forskning visar att moderns egen bröstmjölk är mycket betydelsefull för det nyfödda barnets 
hälsa och utveckling. När ett barn föds för tidigt anpassas modersmjölkens biologiska 
sammansättning för att bättre tillgodose barnets särskilda behov. De allra mest för tidigt 
födda barnen (< 32 veckor) kan till en början ha svårt att amma och tillmatas då med 
urpumpad modersmjölk via sond. Mödrar till för tidigt födda barn kan ha svårt att få igång sin 
mjölkproduktion och att upprätthålla mjölkproduktionen under tiden barnet äter via sond.  
Därtill kan övergången från sondmatning till amning vara motig när barnet väl är moget att ta 
bröstet. I Sverige finns en lång tradition inom neonatalvården att föda upp för tidigt födda 
barn med bröstmjölk. I första hand ges moderns egen mjölk men om modern ej har 
tillräckliga mängder egen mjölk används givarmjölk. Med anledning av detta har ett flertal 
mjölkbanker etablerats runt om i landet, ofta i anslutning till neonatalvården.  
De allra flesta människor i världen bär på ett virus som tillhör virusfamiljen herpes och heter 
cytomegalovirus, förkortat CMV. Viruset smittar via kroppsvätskor, till exempel blod, urin 
och modersmjölk. CMV är den vanligaste orsaken till medfödd infektion hos det nyfödda 
barnet. De flesta smittas dock av viruset under sin uppväxt. CMV är ett virus som kan orsaka 
allvarliga sjukdomstillstånd hos människa om immunförsvaret är försvagat. Hos de flesta 
individer med välfungerande immunförsvar orsakar CMV infektion inte sjukdom. När CMV 
infekterat en människa existerar det kvar i kroppen i en slumrande fas men kan i vissa fall 
reaktiveras och då utsöndras i våra kroppsvätskor. Studier har visat att de allra flesta kvinnor 
som bär på viruset utsöndrar det i sin bröstmjölk efter att de fött barn och att det ammande 
barnet kan smittas av viruset. Om barnet är fullgånget skyddas det av antikroppar från 
modern som går över till fostret via moderkakan i slutet av graviditeten. Fullgångna barn 
brukar därför inte bli sjuka i samband med bröstmjölksöverförd CMV smitta. De barn som 
föds för tidigt har dock ett omoget immunförsvar och saknar de skyddande antikropparna från 
modern och är därför mer infektionskänsliga. Kliniska studier har visat att för tidigt födda 
barn kan utveckla allvarliga sjukdomssymptom i samband med bröstmjölksöverförd CMV 
smitta med allmänpåverkan, lunginflammation, tarminflammation, leverpåverkan och 
påverkan på blodbild.  
För att undvika smittöverföring av CMV via modersmjölk finns det sätt att behandla mjölken 
på innan det ges till det för tidigt födda barnet. Ett sätt är att värmebehandla mjölken, eller 
pastörisera den, vilket avdödar viruset. Nackdelen är att pastörisering förstör många viktiga 
näringsämnen och biologiska komponenter i mjölken som är viktiga för barnets utveckling 
och för att stärka barnets försvar mot infektioner. Ett annat sätt att behandla mjölken på är 
infrysning under några dagar vilket visat sig minska virusmängden i mjölken utan en lika 
skadlig effekt på modersmjölkens beståndsdelar. Rutinmässig infrysning medför däremot att 
tillförseln av den allra första modersmjölken till det för tidigt födda barnet blir fördröjd och 
det kan ha en stor betydelse för tarmslemhinnans utveckling och för uppkomsten av en 
gynnsam bakterieflora i tarmen. Internationellt pågår en omfattande debatt om det finns skäl 
att behandla moderns egen bröstmjölk innan den ges till de allra mest för tidigt födda barnen 
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och trots att ett flertal studier har utförts för att kartlägga konsekvenserna av 
bröstmjölksöverförd smitta i denna patientgrupp så föreligger inget enhetligt konsensus.  
Mot denna bakgrund var syftet med denna avhandling: 
Att i en nationell tvärsnittsstudie utforska gällande rutiner för hantering av bröstmjölk till för 
tidigt födda barn i Sverige (Studie I). 
Att utforska maternella prediktorer för intag av modersmjölk hos extremt för tidigt födda barn 
under nyföddhetsperioden och vid utskrivning från nyföddhetsavdelning (Studie II). 
Att i en pilotstudie utvärdera frekvens och kliniskt uttryck av bröstmjölksöverförd CMV 
infektion hos extremt underburna barn vid Astrid Lindgens barnsjukhus (Studie III). 
Att bedöma om rutinmässig infrysning av modersmjölk minskar smittöverföring av CMV 
och symptom vid CMV infektion hos extremt underburna barn eller påverkar dödlighet och 
sjuklighet hos denna patientgrupp under vårdtiden på sjukhus (Studie IV).  
Att undersöka förekomst av CMV infektion i tarmvävnadsprover från barn med 
nekrotiserande enterokolit, spontan tarmperforation och relaterade kirurgiska tillstånd (Studie 
V). 
Baserat på resultaten i avhandlingen är våra slutsatser och framtida perspektiv:      
Studie I.  
Bröstmjölkshantering skilde sig åt bland de 36 neonatalenheterna i Sverige. Uppdatering av 
nationella riktlinjer kan bidra till att standardisera den praktiska bröstmjölkshanteringen vilket 
leder till förbättrad nutrition och mindre risk för bröstmjölksöverförda infektioner.   
Studie II.  
Gynnsamma prediktorer för intag av modersmjölk de första 6 levnadsveckorna var ett högt 
(>90%) intag av modersmjölk hos barnet under andra levnadsveckan samt 
universitetsutbildning och nordiskt ursprung hos modern. Ett högt modersmjölksintag de 6 
första levnadsveckorna hos barnet och maternell ålder var positivt associerade till uppfödning 
med modersmjölk vid utskrivningen medan maternell övervikt var en ogynnsam prediktor.  
Mödrar till extremt för tidigt födda barn bör uppmuntras tidigt till adekvat urpumpning för att 
främja barnets tillgång till egen mjölk under och efter nyföddhetsperioden. Särskilda insatser 
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bröstmjölksöverförd CMV infektion hos det extremt underburna barnet och för att bedöma 
risk/nytta förhållandet för att ge modersmjölk till denna patientgrupp. 
Studie IV. 
Frekvensen av CMV överföring till extremt för tidigt födda barn som erhöll CMV 
innehållande mjölk var oväntat låg (7%) och samtliga CMV infekterade barn var 
symptomfria. Infrysning av modersmjölk påverkade inte smittöverföringen av CMV. 
Andelen barn med medfödd CMV infektion var relativt hög i studien (2%). Infrysning av 
modersmjölk påverkade inte dödlighet men minskade frekvensen av sen svampsepsis före 
införandet av rutinmässig profylaxbehandling mot svampinfektion. Ytterligare studier är 
nödvändiga för att avgöra om infrysning av modersmjölk skyddar mot uppkomsten av sen 
svampsepsis och om rutinmässig screening av medfödd CMV infektion är indicerad hos 
extremt underburna barn.  
Studie V.  
Två olika CMV specifika proteiner (CMV-IEA och CMV-LA) kunde påvisas med 
immunohistokemi i en hög andel (81% respektive 64%) av tarmvävnadsprover från barn med 
nekrotiserande enterokolit, spontan tarmperforation och relaterade kirurgiska tillstånd. 
Förekomsten av dessa CMV specifika proteiner i kontrolltarmvävnadsprover från tarmfriska 
obducerade barn var endast 20%. Kompletterande CMV-DNA analyser i utvalda CMV-IEA 
positiva tarmvävnadsprover för att bekräfta förekomst av viruset var positiva i 13/13 (100%) 
tarmvävnadsprover med in situ hybridisering och i 4/10 (40%) prover med Taqman PCR 
analys efter laser capture microdissection av CMV-positiva celler. Våra resultat antyder att 
CMV kan ha en bidragande roll i uppkomsten av nekrotiserande enterokolit, spontan 
tarmperforation och relaterade kirurgiska tillstånd och möjligtvis påverka utgång. Framtida 
studier bör riktas mot att hitta adekvat metod för screening av CMV orsakad nekrotiserande 
enterokolit och spontan tarmperforation, för att bättre utforska virusets roll i 
sjukdomsuppkomsten av dessa åkommor och för att utvärdera om CMV inriktad behandling 
kan vara indicerad i vissa fall av dessa sjukdomstillstånd.  
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